UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
SCHEDULE
14A
(Rule
14a-101)
INFORMATION
REQUIRED IN PROXY STATEMENT
SCHEDULE
14A INFORMATION
Proxy
Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
(Amendment
No. )
Filed
by the Registrant ☒
Filed
by a Party other than the Registrant ☐
Check
the appropriate box:
| ☐ |
Preliminary
Proxy Statement |
| |
|
| ☐ |
Confidential,
for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| |
|
| ☒ |
Definitive
Proxy Statement |
| |
|
| ☐ |
Definitive
Additional Materials |
| |
|
| ☐ |
Soliciting
Material Pursuant to §240.14a-12 |
| ABEONA
THERAPEUTICS INC. |
| (Name
of Registrant as Specified in its Charter) |
| |
| |
| (Name
of Person(s) Filing Proxy Statement, if Other Than the Registrant) |
Payment
of Filing Fee (Check the appropriate box):
| ☒ |
No
fee required |
| |
|
| ☐ |
Fee
paid previously with preliminary materials |
| |
|
| ☐ |
Fee
computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |
ABEONA
THERAPEUTICS INC.
6555
Carnegie Ave., 4th Floor
Cleveland,
OH 44103
646-813-4701
NOTICE
OF SPECIAL MEETING OF STOCKHOLDERS
to
be held on Friday, December 20, 2024
PLEASE
TAKE NOTICE that the 2024 Special Meeting of Stockholders (the “Special Meeting”) of Abeona Therapeutics Inc. (the “Company”)
will be held virtually over the Internet on Friday, December 20, 2024, at 9:00 a.m. Eastern Time, for the purpose of approving an increase
in the number of shares of Common Stock reserved for issuance under the Second Amended and Restated Abeona Therapeutics Inc. 2023
Equity Incentive Plan from 3,200,000 to 8,400,000 shares of Common Stock.
In
addition to the foregoing, the Special Meeting will include the transaction of such other business as may properly come before the Special
Meeting, or any adjournment(s), continuation(s), rescheduling(s) or postponement(s) thereof. The Board of Directors has fixed the close
of business on November 7, 2024 (the “Record Date”), as the record date for the determination of stockholders entitled to
receive notice of, and to vote at, the Special Meeting and any adjournment or postponement thereof. Only stockholders of record at the
close of business on the Record Date are entitled to notice of and to vote at the Special Meeting. A complete list of stockholders entitled
to vote at the Special Meeting will be available for inspection by stockholders at our offices during normal business hours, during the
10 days prior to the Special Meeting as well as during the Special Meeting at www.virtualshareholdermeeting.com/ABEO2024SM.
Information
relating to the proposals described above is set forth in the accompanying proxy statement. Please carefully review the proxy statement.
This Proxy Statement is available at www.proxyvote.com.
Stockholders
are invited to attend the Special Meeting to be held virtually over the Internet on Friday, December 20, 2024 at 9 a.m. Eastern Time.
YOUR VOTE IS IMPORTANT. If you do not expect to virtually attend the Special Meeting, or if you do plan to virtually attend but wish
to vote by proxy, please complete, date, sign and mail the enclosed proxy card in the return envelope provided addressed to Vote Processing,
c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717. Proxies will also be accepted as follows: (1) via the Internet by accessing www.proxyvote.com
and following the on-screen instructions or scanning the QR code on the proxy card with your smartphone; (2) by calling toll-free at
1-800-690-6903 from any touch-tone telephone and following the instructions; (3) by signing, dating and returning your proxy card in
the prepaid enclosed envelope and (4) by attending the virtual Special Meeting at www.virtualshareholdermeeting.com/ABEO2024SM.
You should have your proxy card available in front of you when you log onto the Internet or call. You can vote online or by phone until
11:59 p.m. Eastern Time the day before the Special Meeting.
| By
Order of the Board of Directors, |
|
| |
|
| /s/
Vishwas Seshadri |
|
| Vishwas
Seshadri |
|
| President
& Chief Executive Officer |
|
Cleveland,
OH
November
12, 2024
TABLE
OF CONTENTS
PROXY
STATEMENT SUMMARY
This
summary highlights information contained elsewhere in this proxy statement. This summary does not contain all information that you should
consider, and you should review all of the information contained in the proxy statement before voting.
Special
Meeting of Stockholders
| Date: |
December
20, 2024 |
| |
|
| Time: |
9:00a.m.
Eastern Time |
| |
|
| Location: |
Online
only at www.virtualshareholdermeeting.com/ABEO2024SM. Stockholders will not be able to attend the Special Meeting in person. |
| |
|
| Record
Date: |
November
7, 2024 |
| |
|
| Voting: |
Stockholders
as of the Record Date are entitled to vote. Each share of common stock is entitled to one vote. |
Proposals
and Voting Recommendations
Proposal
No. |
|
Proposal |
|
Board
Recommendation |
| |
|
|
|
|
| 1 |
|
To
approve an increase in the number of shares of Common Stock reserved for issuance under the Second Amended and Restated Abeona
Therapeutics Inc. 2023 Equity Incentive Plan from 3,200,000 to 8,400,000 shares of Common Stock |
|
FOR |
| |
|
|
|
|
| 2 |
|
To
consider and vote upon an adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient
votes in favor of Proposal No. 1 |
|
FOR |
Voting
Methods
You
can vote in one of four ways:
| ● |
Visit
www.proxyvote.com to vote VIA THE INTERNET |
| |
|
| ● |
Call
toll-free at 1-800-690-6903 and follow the instructions to vote VIA TELEPHONE |
| |
|
| ● |
Sign,
date and return your proxy card in the prepaid enclosed envelope to vote BY MAIL |
| |
|
| ● |
Attend
the meeting to vote VIA THE INTERNET |
ABEONA
THERAPEUTICS INC.
6555
Carnegie Ave., 4th Floor
Cleveland,
OH 44103
(646)
813-4701
PROXY
STATEMENT
SPECIAL
MEETING OF STOCKHOLDERS
To
Be Held on Friday, December 20, 2024
This
proxy statement is furnished by Abeona Therapeutics Inc., a Delaware corporation (“we,” “us,” “Abeona”
or the “Company”), to holders of its common stock, par value $0.01 per share (“Common Stock”), in connection
with the solicitation of proxies by our Board of Directors (the “Board”) for use at our Special Meeting of Stockholders (the
“Special Meeting”), and at any and all adjournments or postponements thereof. This proxy statement and the accompanying form
of proxy is first being sent to holders of Common Stock on or about November 13, 2024. Our mailing address and the location of our principal
executive offices is 6555 Carnegie Ave., 4th Floor, Cleveland, OH 44103. Our telephone number is (646) 813-4701. The purposes of the
Special Meeting are set forth in the Notice of Special Meeting of Stockholders (the “Notice of Special Meeting”), which accompanies
this Proxy Statement.
We
have adopted a virtual format for our Special Meeting to provide a consistent experience to all stockholders regardless of location.
We have designed the virtual Special Meeting to provide substantially the same opportunities to participate as you would have at an in-person
meeting, including the ability to vote. Detailed instructions on how to vote and submit your questions at the Special Meeting may be
found online at www.virtualshareholdermeeting.com/ABEO2024SM.
All
shares of Common Stock represented by properly executed proxies or voting instruction forms will be voted at the Special Meeting in accordance
with the directions marked on the proxies or voting instruction forms, unless such proxies or voting instruction forms have previously
been revoked. If no directions are indicated on such proxies or voting instruction forms, they will be voted FOR Proposal 1 – to
approve an increase in the number of shares of Common Stock reserved for issuance under the Second Amended and Restated Abeona
Therapeutics Inc. 2023 Equity Incentive Plan from 3,200,000 to 8,400,000 shares of Common Stock.
If
any other matters are properly presented at the Special Meeting for action, the proxy holders will vote the proxies (which confer discretionary
authority upon such holders to vote on such matters) in accordance with their best judgment, subject to compliance with Rule 14a-4(c)
of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Each proxy executed and returned by a stockholder
may be revoked at any time before it is voted by timely submission of a written notice of revocation or by submission of a duly executed
proxy bearing a later date (in either case directed to the Secretary of the Company not later than the day prior to the Special Meeting),
or, if a stockholder is virtually present at the Special Meeting, he or she may elect to revoke his or her proxy and request the right
to vote his or her shares of Common Stock personally.
If
your shares of Common Stock are registered directly in your name with our transfer agent, Odyssey Transfer and Trust Company, you are
considered a “stockholder of record” or a “registered stockholder” of those shares of Common Stock. You
should follow the instructions on the Notice of Special Meeting to ensure that your vote is counted. Alternatively, you may attend virtually
and vote at the Special Meeting.
If
your shares are held in an account at a bank, brokerage firm, or other similar organization (which we refer to as a “broker”),
then you are a beneficial owner of shares held in “street name.” In that case, you will have received these proxy materials
from the bank, brokerage firm, or other similar organization holding your account. As a beneficial owner, you will have to direct your
broker on how to vote the shares held in your account in accordance with your broker’s requirements.
At
the close of business on November 7, 2024, the record date for the Special Meeting (the “Record Date”), the number of issued
and outstanding shares of our Common Stock entitled to vote was 43,593,484. Each share of Common Stock entitles its holder to one vote
with respect to all matters submitted to stockholders for a vote at the Special Meeting. Because the only proposal to be voted on at
the special meeting is expected to be treated as a “non-routine” matter, banks, brokers and other nominees will not have
authority to vote on the proposal unless instructed, so we do not expect there to be any broker non-votes at the special meeting.
A
complete list of Company stockholders entitled to vote at the Special Meeting will be available at our principal executive offices during
normal business hours, at least 10 days prior to the Special Meeting and during the Special Meeting at www.virtualshareholdermeeting.com/ABEO2024SM.
According to the Company’s amended and restated bylaws (the “Bylaws”), the presence, through virtual attendance or
by proxy, of the holders of one-third of the shares of Common Stock outstanding and entitled to vote constitutes a quorum for the conduct
of business at the Special Meeting. Abstentions and broker non-votes are counted as present for purposes of determining whether a quorum
is present.
Proposals
1 and 2 will be approved upon the affirmative vote of a majority of the outstanding shares of Common Stock present through virtual attendance
or by proxy at the Special Meeting and entitled to vote on the respective Proposal. Stockholders may vote “FOR” or “AGAINST,”
or “ABSTAIN” from voting. Abstentions will have the effect of a vote “AGAINST” each of Proposals 1 and 2.
The
Board is not aware of any matters that will be brought before the Special Meeting other than those matters specifically set forth in
the Notice of Special Meeting. However, if any other matter properly comes before the Special Meeting, it is intended that the persons
named in the enclosed form of proxy, or their substitutes acting thereunder, will vote on such matter in accordance with the recommendations
of the Board, or, if no such recommendations are made, in accordance with their best judgment.
All
expenses in connection with solicitation of proxies will be borne by us. We will also request brokers, dealers, banks and voting trustees,
and their nominees, to make available the Notice of Special Meeting, this proxy statement, the accompanying form of proxy to beneficial
owners and will reimburse them for their expenses in forwarding these materials. We expect to solicit proxies primarily by mail, but
our directors, officers and employees may also solicit in person, by telephone or email, on behalf of the Board without additional compensation.
Stockholders
of record as of the Record Date can attend the Special Meeting online by logging onto our virtual forum at www.virtualshareholdermeeting.com/ABEO2024SM
and following the instructions provided on their proxy card, vote instruction card or “Important Notice Regarding the Availability
of Proxy Materials.” To participate in the Special Meeting, you will need the 16-digit control number included on your proxy card,
voter instruction card or “Important Notice Regarding the Availability of Proxy Materials.” If you do not have this control
number at the time of the Special Meeting, you will still be able to attend virtually, but you will not be able to vote or ask questions.
The
virtual Special Meeting platform is fully supported across browsers (Microsoft Edge, Firefox, Chrome, and Safari) and devices (desktops,
laptops, tablets, and cell phones) running the most updated version of applicable software and plugins. Attendees should ensure that
they have a strong Wi-Fi connection wherever they intend to participate in the virtual Special Meeting. Attendees should also give themselves
plenty of time to log in and ensure that they can hear streaming audio prior to the start of the virtual Special Meeting.
Compensation
of Directors
Compensation
for Board Service in 2023. Each director who is not also an Abeona employee is entitled to receive an annual board fee and an annual
committee fee for their service on each Board committee. These fees are paid in cash quarterly. In addition, we reimburse each director,
whether an employee or not, for the expense of attending Board and committee meetings. There were no additional fees paid for service
as a chairperson of a Board committee, with the exception of the Chairman of the Board who receives an additional $30,000 per year for
serving as Chairman. During 2023, the annual board fee was $50,000 and the annual committee fee was $7,500 per committee served.
In
addition, incumbent non-employee directors were each granted equity awards valued at $271,143 for service on the Board in 2023 consisting
of restricted stock. All equity awards were granted on a different date than any equity awards to executive officers. These equity awards
vest one year after the date of grant.
Director
Compensation Table – 2023
The
table below represents the compensation paid to each of our directors who served on the Board during the year ended December 31, 2023,
other than Dr. Seshadri, whose compensation as our President and Chief Executive Officer is set forth under “Executive Compensation
— Summary Compensation Table” below:
| | |
Fees | | |
| | |
| | |
| |
| | |
Earned or | | |
| | |
All | | |
| |
| | |
Paid | | |
Stock | | |
Other | | |
| |
| | |
in Cash | | |
Awards | | |
Compensation | | |
Total | |
| Name | |
($)(1) | | |
($)(2) (3) | | |
($) | | |
($) | |
| Leila Alland, M.D. | |
| 65,000 | | |
| 271,143 | | |
| - | | |
| 336,143 | |
| Mark J. Alvino | |
| 65,000 | | |
| 271,143 | | |
| - | | |
| 336,143 | |
| Michael Amoroso | |
| 80,000 | | |
| 271,143 | | |
| - | | |
| 351,143 | |
| Faith L. Charles | |
| 65,000 | | |
| 271,143 | | |
| - | | |
| 336,143 | |
| Paul Mann (4) | |
| 28,750 | | |
| - | | |
| 14,344 | | |
| 43,094 | |
| Christine Silverstein | |
| 53,750 | | |
| 271,143 | | |
| - | | |
| 324,893 | |
| Todd Wider, M.D. (5) | |
| 28,750 | | |
| - | | |
| 14,344 | | |
| 43,094 | |
| Donald A. Wuchterl | |
| 59,375 | | |
| 271,143 | | |
| - | | |
| 330,518 | |
| (1)
|
Amounts
shown reflect the annual board fee and annual committee fee(s) earned in 2023. |
| |
|
| (2)
|
Represents
the aggregate grant date fair value of 58,689 shares of Common Stock on June 14, 2023, the date the restricted stock awards
were granted ($4.62 per share) as reported on Nasdaq, computed in accordance with ASC 718. Our assumptions in determining fair value
are described in Note 10 of Notes to Consolidated Financial Statements in Part II, Item 8 of the Annual Report. Amounts shown do
not reflect the compensation actually received by the directors. |
| |
|
| (3) |
The
aggregate number of stock awards outstanding for each continuing director as of December 31, 2023 is 58,689. |
| |
|
| (4)
|
Mr.
Mann ceased serving on the Board as of May 17, 2023. His fees earned reflect the partial year of service and he also received a one-time
payment representing the cash value of his unvested equity on the termination date in exchange for a release of claims in connection
with his termination. |
| |
|
(5)
|
Dr.
Wider ceased serving on the Board as of May 17, 2023. His fees earned reflect the partial year of service and he also received a
one-time payment representing the cash value of his unvested equity on the termination date in exchange for a release of claims in
connection with his termination. |
Certain
Relationships and Related Transactions
On
occasion we may engage in certain related party transactions. Pursuant to our Audit Committee charter, our policy is that all related
party transactions are reviewed and approved by the Audit Committee. There were no related party transactions in 2023.
Equity
Compensation Plan Information
The
following table sets forth, as of December 31, 2023, information about shares of Common Stock outstanding and available for issuance
under our existing equity compensation plans.
| Plan Category | |
Number of securities to be issued upon exercise of outstanding options, warrants and rights(1) | | |
Weighted-average exercise price of outstanding options, warrants and rights | | |
Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) | |
| | |
(a) | | |
(b) | | |
(c) | |
| Equity compensation plans approved by security holders: | |
| | | |
| | | |
| | |
| 2023 Equity Incentive Plan(2) | |
| — | | |
| — | | |
| 156,591 | |
| 2015 Equity Incentive Plan(3) | |
| 179,001 | | |
$ | 38.58 | | |
| — | |
| Equity compensation plans not approved by security holders(4) | |
| — | | |
| — | | |
| 859,400 | |
| Total | |
| 179,001 | | |
$ | 38.58 | | |
| 1,015,991 | |
| (1) |
A
total of 1,684,009, 632,410 and 131,750 unvested restricted shares of Common Stock under the 2023 Equity Incentive Plan, 2015
Equity Incentive Plan and 2023 Employment Inducement Equity Incentive Plan, respectively, were excluded from column (a) as those
shares are considered issued at the time of grant. Unvested restricted shares were also excluded from column (c) as they are no longer
available for future issuance. |
| (2) |
As
described in “Proposal 1: Approval of an Increase in the Number of Shares of Common Stock Reserved for Issuance Under
the Second Amended and Restated Abeona Therapeutics Inc. 2023 Equity Incentive Plan” we are seeking stockholder approval of
an increase the share reserve under the Second Amended and Restated Abeona Therapeutics Inc. 2023 Equity Incentive Plan by 5,200,000
shares, from 3,200,000 to 8,400,000 shares, at the Special Meeting. |
| (3) |
No
further grants may be made under the 2015 Equity Incentive Plan. |
| (4) |
On
September 23, 2023, the Company adopted the 2023 Employment Inducement Equity Incentive Plan to provide the Company with an ability
to grant equity incentive compensation as a material inducement for certain individuals to commence employment with the Company within
the meaning of Nasdaq Stock Market Rule 5635(c)(4) and, subject to the adjustment provisions of the 2023 Employment Inducement Equity
Incentive Plan, reserved 1,000,000 shares of Common Stock for issuance pursuant to equity awards granted under the 2023 Employment
Inducement Equity Incentive Plan. |
Security
Ownership of Certain Beneficial Owners and Management
The
Company has determined beneficial ownership of our Common Stock as of November 7, 2024, in accordance with the rules of the SEC. These
rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with
respect to those securities. In addition, these rules require that the Company include shares of Common Stock issuable pursuant to the
vesting of restricted stock units and the exercise of stock options and warrants that are either immediately exercisable or exercisable
within 60 days of November 7, 2024. These shares are deemed to be outstanding and beneficially owned by the person holding those options
or warrants for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding for the purpose
of computing the percentage ownership of any other person. Unless otherwise indicated, the persons or entities identified in this table
have sole voting and investment power with respect to all shares shown as beneficially owned by them, subject to applicable community
property laws.
| | |
Amount and
Nature of |
| |
| |
| | |
Beneficial
Ownership |
| |
| |
| | |
of Common |
| |
Percent of | |
| Name and Address of Beneficial Owner | |
Stock (1) |
| |
Common Stock(2) | |
| Directors and Named Executive Officers: | |
| |
| |
| | |
| Leila Alland, M.D. (3) | |
| 122,192 |
| |
| * | |
| Mark J. Alvino (4) | |
| 76,261 |
| |
| * | |
| Michael Amoroso (5) | |
| 192,033 |
| |
| * | |
| Faith L. Charles (6) | |
| 117,658 |
| |
| * | |
| Christine Silverstein (7) | |
| 117,986 |
| |
| * | |
| Donald A. Wuchterl (8) | |
| 118,438 |
| |
| * | |
| Vishwas Seshadri (9) | |
| 927,388 |
| |
| 2.1 | % |
| Brendan O’Malley (10) | |
| 290,080 |
| |
| * | |
| Joseph Vazzano (11) | |
| 365,217 |
| |
| * | |
| Bernhardt G. Zeiher(12) | |
| 11,044 |
| |
| * | |
| Eric Crombez(13) | |
| 11,044 |
| |
| * | |
| All Directors and Named Executive Officers as a group (consisting of 11 persons) | |
| 2,349,341 |
| |
| 5.4 | % |
| 5% Beneficial Owners: | |
| |
| |
| | |
| Adage Capital Partners, L.P. (14) | |
| 4,210,429 |
| |
| 9.7 | % |
| Nantahala Capital Management, L.P. (15) | |
| 2,499,781 |
| |
| 5.7 | % |
| Millennium
Management LLC(16) | |
| 2,301,628 |
| |
| 5.3 | % |
| Suvretta
Capital Management, LLC(17) | |
| 3,685,503 |
| |
| 8.5 | % |
| Janus
Henderson Group plc(18) | |
| 2,380,667 |
| |
| 5.5 | % |
| (1) |
Includes
outstanding shares of Common Stock held plus all shares of Common Stock issuable upon exercise of options, warrants and other rights
exercisable within 60 days after November 7, 2024. |
| |
|
| (2) |
Based
upon 43,593,484 shares of Common Stock issued and outstanding as of November 7, 2024. |
| |
|
| (3) |
Dr.
Alland is known to beneficially own an aggregate of 118,265 shares of our Common Stock and presently exercisable options for the
purchase of 3,927 shares pursuant to the 2015 Equity Incentive Plan. |
| |
|
| (4) |
Mr.
Alvino is known to beneficially own an aggregate of 72,334 shares of our Common Stock and presently exercisable options for the purchase
of 3,927 shares pursuant to the 2015 Equity Incentive Plan. |
| |
|
| (5) |
Mr.
Amoroso is known to beneficially own an aggregate of 144,365 shares of our Common Stock and presently exercisable options for the
purchase of 47,668 shares of our Common Stock pursuant to the 2015 Equity Incentive Plan. |
| |
|
| (6) |
Ms.
Charles is known to beneficially own an aggregate of 113,731 shares of our Common Stock and presently exercisable options for the
purchase of 3,927 shares of our Common Stock pursuant to the 2015 Equity Incentive Plan. |
| |
|
| (7) |
Ms.
Silverstein is known to beneficially own an aggregate of 97,471 shares of our Common Stock and presently exercisable options for
the purchase of 20,515 shares of our Common Stock pursuant to the 2015 Equity Incentive Plan. |
| |
|
| (8) |
Mr.
Wuchterl is known to beneficially own an aggregate of 114,511 shares of our Common Stock and presently exercisable options for the
purchase of 3,927 shares of our Common Stock pursuant to the 2015 Equity Incentive Plan. |
| |
|
| (9) |
Dr.
Seshadri is known to beneficially own an aggregate of 903,887 shares of our Common Stock and presently exercisable options for the
purchase of 23,501 shares of our Common Stock pursuant to the 2015 Equity Incentive Plan. |
| |
|
| (10) |
Dr.
O’Malley is known to beneficially own an aggregate of 273,289 shares of our Common Stock and presently exercisable options
for the purchase of 16,791 shares of our Common Stock pursuant to the 2015 Equity Incentive Plan. |
| |
|
| (11) |
Mr.
Vazzano is known to beneficially own an aggregate of 365,217 shares of our Common Stock. |
| |
|
(12)
|
Dr.
Zeiher is known to beneficially own an aggregate of 11,044 shares of our Common Stock. |
| (13) |
Dr.
Crombez is known to beneficially own an aggregate of 11,044 shares of our Common Stock. |
| |
|
| (14) |
Based
on information set forth in a Schedule 13G/A filed with the SEC on June 3, 2024 by Adage Capital Management, L.P., Robert Atchinson
and Phillip Gross. Adage Capital Management, L.P. (“ACM”), may be deemed to have beneficial ownership of the shares of
Common Stock directly held by Adage Capital Partners, L.P. (“ACP”) as the investment manager of ACP. Robert Atchinson
and Phillip Gross may be deemed to have beneficial ownership of such shares in their roles as managing director of entities affiliated
with ACM. The address of each of the reporting persons above is 200 Clarendon Street, 52nd Floor, Boston, MA 02116. |
| |
|
| (15) |
Based on information set forth in a Schedule 13G/A filed
with the SEC on February 14, 2024 by Nantahala Capital Management, LLC (“Nantahala”), Wilmot B. Harkey and Daniel Mack.
Nantahala may be deemed to be the beneficial owner of 2,499,781 shares of our Common Stock held by funds and separately managed accounts
under its control, and as the managing members of Nantahala, each of Wilmot B. Harkey and Daniel Mack may be deemed to be a beneficial
owner of those shares of our Common Stock. The 2,499,781 shares of our Common Stock includes 249,529 shares of our Common Stock which
may be acquired by Nantahala within sixty days through the exercise of warrants. Nantahala Capital Management, LLC’s address
is 130 Main St. 2nd Floor, New Canaan, CT 06840. |
| (16) |
Based
on information set forth in a Schedule 13G/A filed with the SEC on October 8, 2024 by Integrated Core Strategies (US) LLC, Millennium
Management LLC and related entities. Integrated Core Strategies (US) LLC may be deemed to have beneficial ownership of 2,267,875
shares of our Common Stock. The shares of our Common Stock potentially beneficially owned by Millennium Management LLC, Millennium
Group Management LLC and Israel A. Englander are held by entities subject to voting control and investment discretion by Millennium
Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of
Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC).
The address of each of the reporting persons above is 399 Park Avenue, New York, NY 10022. |
| |
|
| (17) |
Based
on information set forth in a Schedule 13G filed with the SEC on May 13, 2024 by Suvretta Capital Management, LLC, Averill Master
Fund, Ltd. and Aaron Cowen. Suvretta Capital Management, LLC and Aaron Cowen may be deemed to have beneficial ownership of 3,685,503
shares of our Common Stock and Averill Master Fund, Ltd. may be deemed to have beneficial ownership of 3,273,770 shares of our Common
Stock. Suvretta Capital Management, LLC’s address is 540 Madison Avenue, 7th Floor, New York, NY 10022. Averill Master Fund,
Ltd.’s address is c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, Grand Cayman KY1-1104, Cayman Islands.
Aaron Cowen’s address is c/o Suvretta Capital Management, LLC 540 Madison Avenue, 7th Floor, New York, NY 10022. Averill Master Fund, Ltd.’s address is c/o Maples Corporate Services
Limited, P.O. Box 309, Ugland House, Grand Cayman KY1-1104, Cayman Islands. |
| |
|
| (18) |
Based on information set forth in a Schedule 13G
filed with the SEC on May 9, 2024 by Janus Henderson Group plc and Janus Henderson Biotech Innovation Master Fund Ltd., each of which
may be deemed to have beneficial ownership of 2,380,667 shares of our Common Stock. Janus Henderson Group plc’s address is 201
Bishopsgate, EC2M 3AE, United Kingdom. Janus Henderson Biotech Innovation Master Fund Ltd.’s address is c/o Janus Henderson Investors
US LLC, 151 Detroit Street, Denver, Colorado 80206.
|
To
our knowledge, except as noted above, no person or entity is the beneficial owner of more than 5% of the voting power of the Company’s
Common Stock.
Executive
Compensation
The
following table sets forth the aggregate compensation paid to: (i) our principal executive officer at the end of fiscal year 2023, Vishwas
Seshadri and (ii) our only other executive officers other than our principal executive officer who were serving as an executive officer
at the end of fiscal year 2023, Joseph Vazzano and Brendan O’Malley.
Summary
Compensation Table
| | |
| | |
| | |
| | |
| | |
| | |
Non-Equity | | |
All | | |
| |
| | |
| | |
| | |
| | |
Option | | |
Stock | | |
Incentive Plan | | |
Other | | |
| |
| Name and | |
| | |
Salary | | |
Bonus | | |
Awards | | |
Awards | | |
Compensation | | |
Compensation | | |
Total | |
| Principal Position | |
Year | | |
($) | | |
($)(1) | | |
($)(2) | | |
($)(2) | | |
($)(3) | | |
($)(4) | | |
($) | |
| Vishwas Seshadri | |
| 2023 | | |
| 555,000 | | |
| 533,333 | | |
| - | | |
| 1,357,409 | | |
| 388,500 | | |
| 13,200 | | |
| 2,847,442 | |
| President and Chief Executive Officer | |
| 2022 | | |
| 505,000 | | |
| 125,250 | | |
| - | | |
| 478,016 | | |
| 378,750 | | |
| 12,800 | | |
| 1,499,816 | |
| Joseph Vazzano (5) | |
| 2023 | | |
| 440,000 | | |
| 235,333 | | |
| - | | |
| 571,889 | | |
| 232,320 | | |
| 13,200 | | |
| 1,492,742 | |
| Chief Financial Officer | |
| 2022 | | |
| 390,600 | | |
| 65,100 | | |
| - | | |
| 224,070 | | |
| 231,235 | | |
| 12,200 | | |
| 923,205 | |
| Brendan O’Malley | |
| 2023 | | |
| 422,000 | | |
| 150,000 | | |
| - | | |
| 366,335 | | |
| 217,752 | | |
| 13,200 | | |
| 1,169,287 | |
| General Counsel | |
| 2022 | | |
| 390,600 | | |
| 65,100 | | |
| - | | |
| 224,070 | | |
| 231,235 | | |
| 12,200 | | |
| 923,205 | |
| (1) |
Reflects
cash retention bonuses paid on June 23, 2023 and December 15, 2022. The 2023 retention bonus was to make up for the shortfall in
equity that was granted as compared to the recommended market amount to be granted. The 2022 retention bonus was to retain key talent
to ensure continuity and stability of operations. |
| |
|
| (2) |
Reflects
aggregate grant date fair value for the fiscal years presented, computed in accordance with ASC 718, in respect of option awards
and restricted stock awards, as applicable. Our assumptions in determining fair value are described in Note 10 of Notes to Consolidated
Financial Statements in Part II, Item 8 of the Annual Report. Amounts shown do not reflect the compensation actually received by
the named executive officers. |
| |
|
| (3) |
Amounts
shown reflect target-based cash incentive bonuses earned with respect to the fiscal years presented. For Mr. Vazzano, 2022 amounts
are based on his annualized base salary and prorated for time worked. |
| |
|
| (4) |
Represents
employer matching contributions to the Company’s 401(k) Defined Contribution Plan. |
| |
|
| (5) |
Mr.
Vazzano was appointed as our Chief Financial Officer on March 14, 2022. |
Outstanding
Equity Awards at Fiscal Year-End
The
following table summarizes the aggregate number of option and stock awards held by our named executive officers (“NEOs”)
as of December 31, 2023.
| | |
| | |
Option
Awards | | |
Stock
Awards | |
| | |
| | |
Number
of | | |
Number
of | | |
| | |
| | |
Number
of | | |
Market
Value | |
| | |
| | |
Securities | | |
Securities | | |
| | |
| | |
Shares
or | | |
of
Shares or | |
| | |
| | |
Underlying | | |
Underlying | | |
| | |
| | |
Units | | |
Units
of | |
| | |
| | |
Unexercised | | |
Unexercised | | |
Option | | |
| | |
of
Stock | | |
Stock | |
| | |
| | |
Options | | |
Options | | |
Exercise | | |
Option | | |
That
Have | | |
That
Have | |
| | |
Grant | | |
(#) | | |
(#) | | |
Price | | |
Expiration | | |
Not
Vested | | |
Not
Vested | |
| Name | |
Date | | |
Exercisable | | |
Unexercisable | | |
($) | | |
Date | | |
(#) | | |
($)(1) | |
| | |
| 6/5/2023 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 336,826 | (3) | |
$ | 1,687,498 | |
| | |
| 9/28/2022 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 116,400 | (3) | |
$ | 583,164 | |
| Vishwas
Seshadri | |
| 10/15/2021 | | |
| 6,500 | | |
| 5,500 | (2) | |
$ | 22.75 | | |
| 10/15/2031 | | |
| 1,000 | (3) | |
$ | 5,010 | |
| | |
| 6/1/2021 | | |
| 10,000 | | |
| 6,000 | (2) | |
$ | 42.75 | | |
| 6/1/2031 | | |
| 4,000 | (3) | |
$ | 20,040 | |
| | |
| 6/5/2023 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 141,908 | (4) | |
$ | 710,959 | |
| | |
| 9/28/2022 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 54,563 | (4) | |
$ | 273,358 | |
| Joseph
Vazzano | |
| 7/21/2022 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 9,000 | (4) | |
$ | 45,090 | |
| | |
| 3/14/2022 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 4,500 | (4) | |
$ | 22,545 | |
| | |
| 6/5/2023 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 90,902 | (6) | |
$ | 455,419 | |
| | |
| 9/28/2022 | | |
| | | |
| | | |
| | | |
| | | |
| 54,563 | (6) | |
$ | 273,358 | |
| | |
| 9/20/2021 | | |
| 6,118 | | |
| 4,762 | (5) | |
$ | 30.25 | | |
| 9/20/2031 | | |
| 2,720 | (6) | |
$ | 13,627 | |
| | |
| 3/1/2021 | | |
| 2,752 | | |
| 1,248 | (5) | |
$ | 58.50 | | |
| 3/1/2031 | | |
| 1,000 | (6) | |
$ | 5,010 | |
| Brendan
O’Malley | |
| 5/20/2020 | | |
| 679 | | |
| 44 | (5) | |
$ | 28.75 | | |
| 3/16/2030 | | |
| 250 | (6) | |
$ | 1,253 | |
| | |
| 3/16/2020 | | |
| 1,198 | | |
| 79 | (5) | |
$ | 28.75 | | |
| 3/16/2030 | | |
| - | | |
$ | - | |
| | |
| 5/31/2019 | | |
| 2,200 | (5) | |
| - | | |
$ | 28.75 | | |
| 5/31/2029 | | |
| - | | |
$ | - | |
| (1) |
Calculated
based on our closing share price on December 29, 2023 of $5.01. |
| |
| (2) |
Dr.
Seshadri’s options to purchase shares of Common Stock will vest in the following periods: 12,000 options at $22.75 per share
granted on October 15, 2021 will be fully vested in October 2025 and 16,000 options granted on June 1, 2021 at $42.75 per share will
be fully vested in June 2025. |
| (3) |
Dr.
Seshadri’s restricted stock will vest in the following periods: 2,000 shares granted on October 15, 2021 will be fully vested
in October 2025; 8,000 shares granted on June 1, 2021 will be fully vested in June 2025; 155,200 shares granted on September 28,
2022 will be fully vested in September 2026; and 336,826 shares granted on June 5, 2023 will be fully vested in June 2026. |
| |
| (4) |
Mr.
Vazzano’s restricted stock will vest in the following periods: 8,000 shares granted on March 14, 2022 will be fully vested
in March 2026; 12,000 shares granted on July 21, 2022 will be fully vested in July 2026; 72,750 shares granted on September 28, 2022
will be fully vested in September 2026; and 141,908 shares granted on June 5, 2023 will be fully vested in June 2026. |
| |
| (5) |
Dr.
O’Malley’s options to purchase shares of Common Stock will vest in the following periods: 10,880 options granted on September
20, 2021 at $30.25 per share will be fully vested in September 2025; 4,000 options granted on March 1, 2021 at $58.50 per share will
be fully vested in March 2025; 723 options granted on May 20, 2020 at $28.75 per share will be fully vested in March 2024; 1,277
options granted on March 16, 2020 at $28.75 per share will be fully vested in March 2024 and 2,200 options granted on May 31, 2019
at $28.75 per share were fully vested as of May 2023. |
| |
| (6) |
Dr.
O’Malley’s restricted stock will vest in the following periods: 5,440 shares granted on September 20, 2021 will be fully
vested in September 2025; 2,000 shares granted on March 1, 2021 will be fully vested in March 2025; 750 shares granted on May 20,
2020 will be fully vested in March 2024; 72,750 shares granted on September 28, 2022 will be fully vested in September 2026; and
90,902 shares granted on June 5, 2023 will be fully vested in June 2026. |
Compensation
Pursuant to Agreements and Plans
Employment
Agreements
President
and Chief Executive Officer
Dr.
Seshadri entered into an employment agreement with the Company when he joined as SVP, Head of Research & Clinical Development on
June 1, 2021. In his role as SVP, Head of Research & Clinical Development, Dr. Seshadri received an annual base salary of $400,000
and was eligible for an annual discretionary bonus with a target of 40% of his annual base salary. On June 1, 2021, Dr. Seshadri was
granted stock options to purchase 16,000 shares of Common Stock pursuant to the Company’s 2015 Equity Incentive
Plan, with 25% vesting on June 1, 2022 and the remaining 75% vesting in 36 equal monthly installments thereafter. On June 1, 2021, Dr.
Seshadri was granted 12,000 restricted shares of Common Stock pursuant to the Company’s 2015 Equity Incentive Plan, with 6,000
shares vesting on June 1, 2022 and the remaining 6,000 shares vesting in three installments of 2,000 shares annually thereafter starting
on June 1, 2023.
On
October 15, 2021, Dr. Seshadri was appointed President, Chief Executive Officer, and Director. In his new role as President and Chief
Executive Officer, Dr. Seshadri was initially entitled to receive an annual base salary of $500,000 (which has been subsequently increased
as described above) and is eligible for an annual discretionary bonus with a target of 50% of his annual base salary. In connection with
his appointment to President and Chief Executive Officer, Dr. Seshadri was granted 2,000 shares of restricted stock and options to purchase
12,000 shares of Common Stock. The options vest 25% on the one-year anniversary of the grant date and the remaining 75% vest in 36 equal
monthly installments thereafter. The restricted stock will vest 25% on the one-year anniversary of the grant date and the remaining 75%
vest in equal annual installments over the following 36 months. Dr. Seshadri is eligible to participate in all employee benefit plans
that the Company may establish for similarly situated employees, if and to the extent he is eligible pursuant to the terms of such plans
and Company policies, which may be modified by the Company at its discretion.
Under
the terms of his employment agreement dated October 6, 2021, Dr. Seshadri and the Company may each terminate Dr. Seshadri’s employment
for any reason upon written notice to the other party. If Dr. Seshadri’s employment is terminated by the Company other than for
Cause, or by Dr. Seshadri for Good Reason (as each term is defined in his employment agreement), Dr. Seshadri will be entitled to (i)
a payment equal to the sum of his base salary plus his target annual bonus opportunity, (ii) payment equal to the cost of the premium
for his health coverage under the Company’s health plan for him and his dependents for the 12-month period following his termination
date, (iii) a pro-rata bonus for the year of termination and (iv) accelerated vesting equivalent to 12 months of continued employment
from the Termination Date (disregarding such termination for such purpose) with respect to all unvested equity and any other long-term
incentive awards granted to Dr. Seshadri and then outstanding on the Termination Date. The Company’s obligations in the preceding
sentence are conditioned upon, among other things, Dr. Seshadri’s execution and nonrevocation of a release of claims in favor of
the Company and its affiliates.
If
Dr. Seshadri remains continuously employed through the date of a Change in Control (as that term is defined in his employment agreement),
all outstanding equity compensation awards will become fully vested and exercisable immediately.
Chief
Financial Officer
The
Board appointed Mr. Vazzano as Chief Financial Officer effective March 14, 2022. He was entitled to an annual base salary of $360,000,
and a target annual bonus opportunity equal to 40% of his base salary. On March 14, 2022, Mr. Vazzano was granted 8,000 restricted shares
of Common Stock pursuant to the Company’s 2015 Equity Incentive Plan, with 25% vesting on each of March 14, 2023, March 14, 2024,
March 14, 2025 and March 14, 2026. Mr. Vazzano is eligible to participate in all employee benefit plans that the Company may establish
for similarly situated employees, if and to the extent he is eligible pursuant to the terms of such plans and Company policies, which
may be modified by the Company at its discretion.
Pursuant
to his employment agreement dated February 28, 2022, upon achievement of certain corporate actions effective July 2, 2022, Mr. Vazzano’s
annual base salary was increased to $400,000 (which has been subsequently increased as described above), and he was granted 12,000 restricted
shares of Common Stock pursuant to the Company’s 2015 Equity Incentive Plan, with 25% vesting on each of July 21, 2023, July 21,
2024, July 21, 2025 and July 21, 2026.
Under
the terms of his employment agreement, Mr. Vazzano and the Company may each terminate Mr. Vazzano’s employment for any reason upon
written notice to the other party. If Mr. Vazzano’s employment is terminated by the Company other than for Cause, or by Mr. Vazzano
for Good Reason (as each term is defined in his employment agreement), Mr. Vazzano will be entitled to (i) a payment equal to the sum
of 12 months of his annual base salary plus 12 months of his annual target annual bonus opportunity and (ii) payment equal to the cost
of the premium for his health coverage under the Company’s health plan for him and his dependents for the 12-month period following
his termination date. If Mr. Vazzano’s employment is terminated by the Company other than for Cause, or by Mr. Vazzano for Good
Reason (as each term is defined in his employment agreement) within 12 months following a Change of Control, Mr. Vazzano will be entitled
to (i) a payment equal to the sum of 12 months of his annual base salary plus 12 months of his annual target annual bonus opportunity
and (ii) payment equal to the cost of the premium for his health coverage under the Company’s health plan for him and his dependents
for the 12-month period following his termination date. The Company’s obligations in the preceding sentence are conditioned upon,
among other things, Mr. Vazzano’s execution and nonrevocation of a release of claims in favor of the Company and its affiliates.
If
Mr. Vazzano remains continuously employed through the date of a Change in Control (as that term is defined in his employment agreement),
all outstanding equity compensation awards will become fully vested and exercisable immediately.
General
Counsel
Dr.
O’Malley joined Abeona in 2019 as Chief IP Counsel. He was entitled to an annual base salary of $321,000, effective January 1,
2021 and a target annual bonus opportunity equal to 35% of his base salary. The amount of the annual bonus actually paid depended on
the extent to which the performance goals are achieved or exceeded as determined by the Board. Dr. O’Malley is eligible to participate
in all employee benefit plans that the Company may establish for similarly situated employees, if and to the extent he is eligible pursuant
to the terms of such plans and Company policies, which may be modified by the Company at its discretion.
On
September 20, 2021, Dr. O’Malley was appointed SVP, General Counsel. In this role, Dr. O’Malley received an annual base salary
of $372,000 (which has been subsequently increased as described above) and was eligible for an annual discretionary bonus with a target
of 40% of his annual base salary. In connection with his appointment as SVP, General Counsel, Dr. O’Malley was granted 5,440 shares
of restricted stock and options to purchase 10,880 shares of Common Stock. The options vest 25% on the one-year anniversary of
the grant date and the remaining 75% vest in 36 equal monthly installments thereafter. The restricted stock will vest 25% on the one-year
anniversary of the grant date and the remaining 75% vest in equal annual installments over the following 36 months.
Under
the terms of his employment agreement dated September 16, 2021, Dr. O’Malley and the Company may each terminate Dr. O’Malley’s
employment for any reason upon written notice to the other party. If Dr. O’Malley’s employment is terminated by the Company
other than for Cause, or by Dr. O’Malley for Good Reason (as each term is defined in his employment agreement), Dr. O’Malley
will be entitled to (i) a payment equal to the sum of 12 months of his annual base salary plus 12 months of his annual target annual
bonus opportunity and (ii) payment equal to the cost of the premium for his health coverage under the Company’s health plan for
him and his dependents for the 12-month period following his termination date. If Dr. O’Malley’s employment is terminated
by the Company other than for Cause, or by Dr. O’Malley for Good Reason (as each term is defined in his employment agreement) within
12-months following a Change of Control, Dr. O’Malley will be entitled to (i) a payment equal to the sum of 12 months of his annual
base salary plus 12 months of his annual target annual bonus opportunity and (ii) payment equal to the cost of the premium for his health
coverage under the Company’s health plan for him and his dependents for the 12-month period following his termination date. The
Company’s obligations in the preceding sentence are conditioned upon, among other things, Dr. O’Malley’s execution
and nonrevocation of a release of claims in favor of the Company and its affiliates.
If
Dr. O’Malley remains continuously employed through the date of a Change in Control (as that term is defined in his employment agreement),
all outstanding equity compensation awards will become fully vested and exercisable immediately.
Retirement
Benefits
The
Company’s executives are provided usual and customary retirement benefits available to all employees, including the NEOs. These
include a 401(k) plan, life insurance, accidental death and dismemberment insurance, medical and dental insurance, vision insurance,
long-term disability insurance and a Company-sponsored pension plan. We provide matching contributions under our 401(k) plan to all employees,
including the NEOs.
Compensation
Committee Discussion on Executive Compensation
The
Compensation Committee operates under a written charter adopted by the Board and is responsible for making all compensation decisions
for the Company’s directors and named executive officers, including determining base salary and annual incentive compensation amounts
and recommending stock option grants and other stock-based compensation under our equity incentive plans. The Compensation Committee
charter can be found on our website at www.abeonatherapeutics.com under “Investors & Media—Corporate Governance—Governance
Documents.”
Pay
Versus Performance
In
accordance with rules adopted by the SEC pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, we are providing
the following disclosure, as it applies to smaller reporting companies, regarding executive “Compensation Actually Paid”
(“CAP”), as calculated under applicable SEC rules, for our principal executive officer(s) (“PEO(s)”) and our
other named executive officers (“non-PEO NEOs”) and certain financial performance measures for the fiscal years ended December
31, 2023, 2022 and 2021.
In
determining the CAP to our PEO(s) and the CAP to our non-PEO NEOs, we are required to make various adjustments to the total compensation
amounts that have been reported in the Summary Compensation Table (“SCT”), as the SEC’s valuation methods for this
section differ from those required in the SCT. Information regarding the methodology for calculating CAP to our PEO(s) and the CAP to
our non-PEO NEOs, including details regarding the amounts that were deducted from, and added to, the SCT totals to arrive at the values
presented for CAP, are provided in the footnotes to the table. Note that for non-PEO NEOs, compensation is reported as an average.
Pay
Versus Performance
| Year | |
Summary
Compensation
Table Total
for Dr.
Seshadri (1) | | |
Summary
Compensation
Table Total
for Mr.
Amoroso (1) | | |
Compensation
Actually Paid
to Dr.
Seshadri (1)(2) | | |
Compensation
Actually Paid
to Mr.
Amoroso (1)(2) | | |
Average
Summary
Compensation
Table Total
for Non-PEO
NEOs | | |
Average
Compensation
Actually Paid
to Non-PEO
NEOs | | |
Value of
Initial Fixed
$100
Investment
Based on
Total
Shareholder
Return | | |
Net
Income
(Loss) (in
thousands) | |
| 2023 | |
$ | 2,847,442 | | |
| — | | |
$ | 3,458,338 | | |
| — | | |
$ | 1,331,015 | | |
$ | 1,588,304 | | |
$ | 12.76 | | |
$ | (54,188 | ) |
| 2022 | |
$ | 1,499,816 | | |
| — | | |
$ | 1,304,561 | | |
| — | | |
$ | 656,543 | | |
$ | 513,329 | | |
$ | 7.85 | | |
$ | (39,696 | ) |
| 2021 | |
$ | 1,566,475 | | |
$ | 3,064,987 | | |
$ | 570,644 | | |
$ | 541,560 | | |
$ | 1,374,544 | | |
$ | 620,407 | | |
$ | 21.46 | | |
$ | (84,936 | ) |
(1)
During 2021, Mr. Amoroso served as our PEO from January 1, 2021 to October 14, 2021. Dr. Seshadri has served as our PEO since October
15, 2021.
(2)
Deductions from, and additions to, total compensation as reported in the SCT by year to calculate CAP include:
| | |
| |
| | |
| | |
| | |
| | |
| | |
Subtract | | |
| |
| | |
| |
| | |
| | |
| | |
| | |
| | |
Value of | | |
| |
| | |
| |
| | |
| | |
| | |
Add
Change | | |
Add
Change | | |
Equity Awards | | |
| |
| | |
| |
| | |
| | |
| | |
in | | |
in | | |
that | | |
| |
| | |
| |
| | |
| | |
Add | | |
Value of | | |
Value of | | |
Failed to | | |
| |
| | |
| |
Summary Compensation | | |
Subtract Stock | | |
Year-End Equity | | |
Prior
Equity | | |
Vested
Equity | | |
Meet Vesting | | |
Compensation Actually | |
| | |
| |
Table Total | | |
Awards | | |
Value | | |
Awards | | |
Awards | | |
Conditions | | |
Paid | |
| Year | |
Executive(s) | |
($) | | |
($) | | |
($) | | |
($) | | |
($) | | |
($) | | |
($) | |
| 2023 | |
Dr. Seshadri | |
| 2,847,442 | | |
| (1,357,409 | ) | |
| 1,687,498 | | |
| 246,521 | | |
| 34,285 | | |
| — | | |
| 3,458,338 | |
| | |
Other NEOs | |
| 2,662,029 | | |
| (938,224 | ) | |
| 1,166,378 | | |
| 253,501 | | |
| 32,924 | | |
| — | | |
| 3,176,609 | |
| 2022 | |
Dr. Seshadri | |
| 1,499,816 | | |
| (478,016 | ) | |
| 478,016 | | |
| (128,280 | ) | |
| (66,975 | ) | |
| — | | |
| 1,304,561 | |
| | |
Other NEOs | |
| 1,969,630 | | |
| (565,340 | ) | |
| 509,740 | | |
| (82,571 | ) | |
| (31,546 | ) | |
| (259,927 | ) | |
| 1,539,986 | |
| 2021 | |
Dr. Seshadri | |
| 1,566,475 | | |
| (1,303,070 | ) | |
| 307,239 | | |
| — | | |
| — | | |
| — | | |
| 570,644 | |
| | |
Mr. Amoroso | |
| 3,064,987 | | |
| (2,602,910 | ) | |
| 370,580 | | |
| (237,664 | ) | |
| (53,434 | ) | |
| — | | |
| 541,560 | |
| | |
Other NEOs | |
| 2,749,088 | | |
| (1,762,934 | ) | |
| 413,824 | | |
| (156,701 | ) | |
| (2,462 | ) | |
| — | | |
| 1,240,814 | |
Description
of Relationship Between PEOs and Non-PEO NEO Compensation Actually Paid and Company Total Shareholder Return (“TSR”)
The
following chart sets forth the relationship between the average Compensation Actually Paid to our PEOs, the average of Compensation Actually
Paid to our Non-PEO NEOs, and the Company’s cumulative TSR over the three most recently completed fiscal years.
Description
of Relationship Between PEOs and Non-PEO NEO Compensation Actually Paid and Net Income
The
following chart sets forth the relationship between the average Compensation Actually Paid to our PEOs, the average of Compensation Actually
Paid to our Non-PEO NEOs, and our Net Income during the three most recently completed fiscal years.
Proposal
to Be Voted Upon
PROPOSAL
1
APPROVAL
OF AN Increase in the Number of Shares OF COMMON STOCK Reserved for Issuance Under the
Second Amended and Restated Abeona Therapeutics Inc. 2023 Equity Incentive Plan
On
November 1, 2024, the Board adopted, subject to stockholder approval, an amendment (the “Plan Amendment”) to the Amended
and Restated Abeona Therapeutics Inc. 2023 Equity Incentive Plan (the “2023 Equity Incentive Plan”) to increase the number
of shares of our Common Stock authorized for issuance thereunder from 3,200,000 to 8,400,000 shares. The Equity Incentive Plan as amended
by the Plan Amendment is referred to below as the “Second Amended and Restated 2023 Equity Incentive Plan.” Other than the
increase in the share reserve, no other substantive changes are contemplated to the Second Amended and Restated 2023 Equity Incentive
Plan.
Why
You Should Vote FOR the Amendment to the 2023 Equity Incentive Plan
Abeona’s
current overhang is 8.8% which is well below industry norms of a total overhang of 22.2% at the median (50th percentile) and 25.9% at
the 75th percentile. Overhang is calculated as the sum of outstanding options, unvested RSUs, and shares not subject to outstanding awards
and available for issuance (together, the “Numerator”) divided by the sum of the Numerator and shares of Common Stock
outstanding as of November 7, 2024.
As
of December 31, 2023, we had 84 full-time employees. As of November 7, 2024 this number has grown to 127 full-time employees and is expected
to significantly increase in 2025. As Abeona transitions from a research and development company to a commercial stage company, Abeona
is building out its’ manufacturing and commercial infrastructure. A key component of this build out is talent retention. Equity
incentive compensation programs play a pivotal role in our efforts to attract and retain key personnel essential to the Company’s
long-term growth commercially and our ultimate financial success. The Board of Directors and management are asking our stockholders to
approve the Plan Amendment to assist the Company in attracting and retaining qualified personnel. If our stockholders do not approve
the Plan Amendment we will be limited in our ability to continue to issue awards in numbers sufficient to attract and motivate the highly
skilled employees we need to recruit and retain, due to low share reserves remaining in the 2023 Equity Incentive Plan and the dilution
to our share reserve and outstanding equity awards from the increase in our stock outstanding from recent financing activities, and our
employees’ motivation and incentives will be negatively affected.
Offering
a broad-based equity compensation program is vital to attracting and retaining highly skilled people in the highly competitive life sciences
industry. The Company uses equity awards to increase incentives on the part of employees, non-employee directors, consultants and other
key advisors who provide important services to the Company. The Board of Directors and management believes that providing an equity stake
in the future success of our Company motivates these individuals to achieve our long-term business goals and to increase stockholder
value. Their innovation and productivity are critical to our success. Accordingly, approving the Plan Amendment is in the best interest
of our stockholders because equity awards help us to:
| ● |
attract,
motivate and retain talented employees and directors; |
| |
|
| ● |
align
employee and stockholder interests; and |
| |
|
| ● |
link
employee compensation with Company performance. |
The
Board of Directors and management strongly believe that the approval of the Plan Amendment will enable us to achieve our goals
in attracting and retaining our most valuable asset: our employees and other service providers.
In
its determination to approve the amendment to the 2023 Equity Incentive Plan, the Compensation Committee considered an analysis prepared
by independent compensation consultants engaged by the Compensation Committee and management, which included an analysis of our historical
share usage and other key metrics including burn rate, dilution, and overhang compared to the historical market data of 67 biotechnology
companies with a market capitalization ranging from $200 million to $500 million. This dataset showed a 3-year average net burn rate
of 5.4% at the median (50th percentile) and 7.1% at the 75th percentile. This same dataset also showed a total overhang of 22.2% at the
median (50th percentile) and 25.9% at the 75th percentile. As it relates to our equity grant practices, we would point out:
| |
● |
Current
Situation: Abeona needs the additional 5,200,000 shares of Common Stock requested in
the Plan Amendment to retain and motivate the talent necessary to execute our potential commercialization
of pz-cel, research and development objectives and long-term strategy. In our current cash
constrained environment, there is significant risk associated with an inability to timely
deliver equity compensation. As of November 7, 2024, we have only 40,473 shares of Common
Stock remaining for future grant under the 2023 Equity Incentive Plan. The additional
requested shares brings our overhang from 8.8% to 17.7% which is more in line with current
industry levels, but still below the median of peer companies.
|
| |
|
|
| |
● |
Historical
Annual Share Usage: Abeona has historically granted equity in a responsible and carefully
considered manner. Our 3-year average net burn rate is 4.7%. This average net burn rate is
well within market norms and below the median of market data for similarly situated companies.
Annual net burn rate is calculated by dividing (i) the sum of options and RSA’s granted
in the applicable year (inclusive of forfeitures and cancellations) by (ii) shares of Common
Stock outstanding as of fiscal year end.
|
| |
|
|
| |
● |
Median
(50th percentile) Overhang with Share Request: If approved, the proposal to add 5,200,000 shares of Common Stock would
result in an overhang of 16.7% for the 2023 Equity Incentive Plan (this would be equal to 17.7% if we included our inducement plan
which is reserved for new hires who are critical in order for us to scale up our manufacturing and commercial activities). This is
consistent with historical levels and slightly below the median of market data for similarly situated companies. Overhang is calculated
as the sum of outstanding options, unvested RSUs, and shares not subject to outstanding awards and available for issuance (together,
the “Numerator”) divided by the sum of the Numerator and shares of Common Stock outstanding as of November 7,
2024. |
Without
an appropriate reserve of shares of Common Stock to grant competitive equity-based incentives, we would be forced to consider cash replacement
alternatives to provide a market-competitive total compensation package necessary to attract, retain and motivate the talent critical
to our future successes. These cash replacement alternatives could, among other things, reduce the cash available for investment in growth
and development and cause a loss of employee motivation to achieve superior performance over a longer period of time. Equity-based incentives,
by contrast, directly align a portion of the compensation of our service providers with the economic interests of our stockholders.
For
that reason, the Company has structured the Second Amended and Restated 2023 Equity Incentive Plan to provide flexibility in designing
equity incentive programs with a broad array of equity incentives, such as stock options, stock appreciation rights (“SARs”),
stock awards and restricted stock units and implement competitive incentive compensation programs for its employees and non-employee
directors. The Second Amended and Restated 2023 Equity Incentive Plan will continue to be the only plan under which new equity awards
may be granted to our current employees and other service providers. If this Proposal 1 is not approved, then we would be at a disadvantage
against our competitors for recruiting, retaining and motivating individuals critical to our success and could be forced to increase
cash compensation, thereby reducing resources available to meet our business needs.
Dilution
Analysis
The
table below shows our potential dilution levels based on our Common Stock outstanding as of November 7, 2024, the new shares of Common
Stock requested for issuance under the Second Amended and Restated 2023 Equity Incentive Plan and our total equity awards outstanding
as of September 30, 2024. The Board believes that the number of shares of Common Stock requested under the Second Amended and
Restated 2023 Equity Incentive Plan represents a reasonable amount of potential equity dilution and will allow us to continue granting
equity awards.
| Stock Options Outstanding as of September 30, 2024 | |
| 177,138 | |
| Weighted Average Exercise Price of Stock Options Outstanding as of September 30, 2024 | |
$ | 38.62 | |
| Weighted Average Remaining Term of Stock Options Outstanding as of September 30, 2024 | |
| 6.09 years | |
| Outstanding Full Value Awards as of September 30, 2024(1) | |
| 3,268,414 | |
| Total Equity Awards Outstanding as of September 30, 2024(2) | |
| 3,445,552 | |
| Shares of Common Stock Available for Grant under
Other Plans as of September 30, 2024(3) | |
| 725,473 | |
| Shares of Common Stock Requested for the Second Amended and Restated 2023 Equity Incentive Plan | |
| 5,200,000 | |
| Total Potential Overhang under the 2023 Equity Incentive Plan(4) | |
| 9,371,025 | |
| Shares of Common Stock Outstanding as of November 7, 2024 | |
| 43,593,484 | |
| Fully Diluted Shares of
Common Stock(5) | |
| 52,964,509 | |
| Potential Dilution of 5,200,000 Shares of Common Stock as a Percentage of Fully Diluted Shares | |
| 9.8 | % |
(1)
“Full Value Awards” includes restricted stock awards granted under prior plans and as inducement awards that qualify for
the inducement grant exception to the shareholder approval requirements of the Nasdaq Stock Market set forth in Rule 5635(c)(4) (“Inducement
Awards”).
(2)
“Total Equity Awards” represents the sum of outstanding stock options and outstanding Full Value Awards, in each case as
of September 30, 2024.
(3)
“Shares of Common Stock Available for Grant under Other Plans” represents 40,473 shares of Common Stock still
available to be granted under the 2023 Incentive Plan and 685,000 shares of Common Stock available to be granted under the 2023
Employment Inducement Equity Incentive Plan.
(4)
“Total Potential Overhang” includes the sum of the total number of equity awards outstanding as of September 30, 2024, the
number of shares of Common Stock available for Grant under Other Plans as of September 30, 2024, and the number of shares requested
for the Second Amended and Restated 2023 Equity Incentive Plan.
(5)
“Fully Diluted Shares of Common Stock” reflects the sum of the total number of shares of Common Stock outstanding
as of November 7, 2024, the total number of equity awards outstanding as of September 30, 2024, the number of shares of Common Stock
available for Grant under Other Plans as of September 30, 2024, and the number of additional shares of Common Stock requested
for grant under the Second Amended and Restated 2023 Equity Incentive Plan.
Burn
Rate
In
connection with our stock-based compensation programs, we are committed to using equity incentive awards prudently and within reasonable
limits. Accordingly, we closely monitor our equity award “burn rate” each year. Our annual burn rate is determined by dividing
the number of shares of Common Stock subject to equity-based awards we grant in a calendar year by the weighted average number
of our fully-diluted shares of Common Stock outstanding for that calendar year. The average annual burn rate for the years 2023, 2022
and 2021 was 9.0%. We anticipate that the share reserve under the Second Amended and Restated 2023 Equity Incentive Plan will enable
us to fund our equity compensation program for approximately three years. While the Company believes this is a reasonable estimate of
how long the share reserve would last, the actual period for which the proposed Share reserve will fund our equity compensation program
may be shorter or longer than three years, depending on changes in our granting practices, stock price and headcount growth.
Highlights
of the Second Amended and Restated 2023 Equity Incentive Plan
The
Second Amended and Restated 2023 Equity Incentive Plan contains a number of provisions that we believe are consistent with best practices
in equity compensation and which protect the stockholders’ interests, as described below:
| ● |
No
evergreen authorization. The Second Amended and Restated 2023 Equity Incentive Plan does not contain an “evergreen”
Share reserve, meaning that the Share reserve will not be increased without further stockholder approval. |
| ● |
No
liberal share recycling provisions. The Second Amended and Restated 2023 Equity Incentive Plan prohibits the re-use of shares
of Common Stock withheld or delivered to satisfy the exercise price of a stock option or base price of a SAR or to satisfy tax
withholding requirements associated with any award. The Second Amended and Restated 2023 Equity Incentive Plan also prohibits “net
share counting” upon the exercise of stock options or SARs and prohibits the re-use of shares of Common Stock purchased
on the open market with the proceeds of option exercises. |
| |
|
| ● |
Limit
on awards to non-employee directors. The Second Amended and Restated 2023 Equity Incentive Plan imposes an aggregate limit on
the value of awards that may be granted, when aggregated with cash fees that may be paid, to each non-employee director for services
as a non-employee director in any year to $500,000 in total value. |
| |
|
| ● |
Minimum
vesting requirements. The Second Amended and Restated 2023 Equity Incentive Plan requires a one-year minimum vesting schedule
for awards, except that up to 5% of the shares of Common Stock reserved for issuance (subject to certain adjustments) are
available for grant without regard to this requirement, and awards granted to non-employee directors on the date of an annual stockholders’
meeting satisfy this requirement if they provide for vesting at the stockholders’ meeting immediately following the grant date
(but in any event not less than 50 weeks following the date of grant). |
| |
|
| ● |
Ban
on in-the-money stock options and SARs. The Second Amended and Restated 2023 Equity Incentive Plan prohibits the grant of stock
options or stock appreciation rights with an exercise price or base price that is less than fair market value on the date of grant. |
| |
|
| ● |
No
repricing or grant of discounted stock options or SARs. The Second Amended and Restated 2023 Equity Incentive Plan prohibits
repricing of options or SARs either by amending an existing award or substituting a new award for a cancelled award that has an exercise
price or base amount less than the exercise price or base amount applicable to the original award. |
| |
|
| ● |
No
single-trigger acceleration. The Second Amended and Restated 2023 Equity Incentive Plan does not provide for automatic vesting
acceleration of awards in connection with a change in control of the Company. |
| |
|
| ● |
No
dividends on unvested awards. The Second Amended and Restated 2023 Equity Incentive Plan prohibits dividends or dividend equivalents
to be granted in connection with stock options or SARs and prohibits payment of dividends or dividend equivalents on unvested awards
until the underlying awards have vested. |
| |
|
| ● |
Subject
to applicable clawback policies. Awards granted under the Second Amended and Restated 2023 Equity Incentive Plan are subject
to any applicable clawback or recoupment policies, share trading policies, and other policies that may be approved or implemented
by the Board or the Compensation Committee from time to time. |
| |
|
| ● |
Administered
by an independent committee. The Second Amended and Restated 2023 Equity Incentive Plan will be administered by an independent
committee of the Board. |
Summary
of the Second Amended and Restated 2023 Equity Incentive Plan
The
material terms of the Second Amended and Restated 2023 Equity Incentive Plan are summarized below. This summary of the Second Amended
and Restated 2023 Equity Incentive Plan is not intended to be a complete description of the Second Amended and Restated 2023 Equity Incentive
Plan and is qualified in its entirety by the actual text of the Second Amended and Restated 2023 Equity Incentive Plan attached hereto
as Appendix A. Capitalized terms used, but not defined, in the following summary have the meaning assigned to those terms in the Second
Amended and Restated 2023 Equity Incentive Plan.
Purpose
The
Second Amended and Restated 2023 Equity Incentive Plan is intended to provide participants with an incentive to contribute materially
to the Company’s growth by aligning the economic interests of the participants with those of the Company’s stockholders.
Types
of Awards
The
Second Amended and Restated 2023 Equity Incentive Plan provides for the issuance of stock options (including incentive stock options
and nonqualified stock options), SARs, stock awards, stock units, and other stock-based awards to employees, non-employee directors,
and consultants of the Company or its subsidiaries.
Administration
The
Second Amended and Restated 2023 Equity Incentive Plan is administered by the Compensation Committee. The Compensation Committee can
delegate authority to administer the Second Amended and Restated 2023 Equity Incentive Plan to one or more subcommittees of the Compensation
Committee, as it determines to be appropriate. In addition, subject to compliance with applicable laws and applicable stock exchange
requirements, the Compensation Committee may delegate some or all of its authority to our chief executive officer or our chief financial
officer, with respect to grants of awards to employees or advisors and consultants who are not executive officers or directors subject
to reporting obligations under Section 16 of the Exchange Act.
The
Compensation Committee (1) determines the individuals who will receive awards under the Second Amended and Restated 2023 Equity Incentive
Plan; (2) determines the type, size, terms and conditions of awards under the Second Amended and Restated 2023 Equity Incentive Plan;
(3) determines when grants of awards will be made and the duration of any applicable exercise or restriction period, including the criteria
for exercisability and the acceleration of exercisability; (4) determines the amounts payable based on whether performance goals were
met, with discretion to make adjustments to the amounts payable as the Compensation Committee deems appropriate and in the Company’s
best interests; (5) determines when to amend previously granted awards, subject to the limitations set forth in the Second Amended and
Restated 2023 Equity Incentive Plan; (6) determines the terms and guidelines that apply to individuals living outside the U.S. (if any)
who receive grants under the Second Amended and Restated 2023 Equity Incentive Plan; and (7) assesses deal with any other matters arising
under the Second Amended and Restated 2023 Equity Incentive Plan.
The
term “Committee” in this description of the Second Amended and Restated 2023 Equity Incentive Plan will refer to the Compensation
Committee, our Board, or any subcommittee, as applicable, that has authority with respect to a specific grant.
Shares
Subject to the Second Amended and Restated 2023 Equity Incentive Plan
Subject
to adjustment described below, our Second Amended and Restated 2023 Equity Incentive Plan authorizes the issuance or transfer of up to
8,400,000 shares of Common Stock. The Second Amended and Restated 2023 Equity Incentive Plan also provides that shares of Common
Stock reserved for issuance under the Prior Plan that remain available for grant as of the Effective Date and shares of Common
Stock underlying any outstanding award granted under the Prior Plan that, following the Effective Date of the Second Amended and
Restated 2023 Equity Incentive Plan, expires, or is terminated, surrendered, cancelled, exchanged, or forfeited for any reason without
issuance of such shares of Common Stock will be available for new grants under the Second Amended and Restated 2023 Equity Incentive
Plan. Subject to adjustment, as described below, the aggregate number of shares of Common Stock available for issuance
or transfer under the Second Amended and Restated 2023 Equity Incentive Plan pursuant to incentive stock options cannot exceed 8,400,000
shares of Common Stock.
The
shares of Common Stock issuable under the Second Amended and Restated 2023 Equity Incentive Plan may be drawn from shares of
Common Stock of authorized but unissued common stock or from shares of Common Stock that we acquire, including shares of
Common Stock purchased on the open market.
If
awards granted under the Second Amended and Restated 2023 Equity Incentive Plan expire, terminate, or are surrendered, cancelled, forfeited,
or exchanged without having been exercised, vested or paid in shares of Common Stock , subject to such awards will again be available
for purposes of the Second Amended and Restated 2023 Equity Incentive Plan. Shares of Common Stock surrendered in payment of an
option’s exercise price, including options granted under the Prior Plan, are not available for re-issuance under the Second Amended
and Restated 2023 Equity Incentive Plan. Furthermore, shares of Common Stock withheld or surrendered for payment of taxes with
respect to awards, including such awards granted under the Prior Plan, are not available for reissuance. If SARs are granted, the full
number of shares of Common Stock subject to the SARs are considered issued under the Second Amended and Restated 2023 Equity Incentive
Plan, without regard to the number of shares of Common Stock issued upon exercise of the SARs. If grants of awards are settled
in cash rather than shares of Common Stock , any shares of Common Stock that were previously subject to such awards will
again be available for issuance or transfer under the Second Amended and Restated 2023 Equity Incentive Plan. If we repurchase the shares
of Common Stock on the open market with proceeds from an option’s exercise price (including options granted under the Prior
Plan), then such shares of Common Stock cannot be made available for issuance under the Second Amended and Restated 2023 Equity
Incentive Plan.
The
number of shares of Common Stock available under the Second Amended and Restated 2023 Equity Incentive Plan will not be reduced
by the shares of Common Stock that are issued or transferred under awards made pursuant to an assumption, substitution, or exchange
for previously granted awards of a company that we acquired in a transaction. Additionally, subject to applicable stock exchange listing
and Code requirements, shares of Common Stock available under an acquired company’s stockholder approved plan, as adjusted,
may be used by the Company for grants of awards under the Second Amended and Restated 2023 Equity Incentive Plan, and they will not reduce
the Second Amended and Restated 2023 Equity Incentive Plan’s Share reserve.
The
closing price of a share of Common Stock as reported on Nasdaq on November 7, 2024 was $6.38 per common share.
Non-Employee
Director Limit
Subject
to adjustment, as described below, the maximum aggregate grant date value of shares of Common Stock (as determined for financial
reporting purposes) granted to any non-employee director in a calendar year, taken together with any cash fees earned by such non-employee
director for services rendered as a non-employee director during the calendar year, cannot exceed $500,000 in total value. This calculation
excludes the value of any dividend equivalents paid pursuant to grants of awards from any previous year.
Adjustments
If
there is any change in the number or kind of shares of Common Stock outstanding because of (i) a stock dividend, spinoff, recapitalization,
stock split, reverse stock split, or combination or exchange of shares; (ii) a merger, reorganization, or consolidation; (iii) a reclassification
or change in par value of shares of Common Stock; or (iv) any other extraordinary or unusual event affecting the outstanding common
stock as a class without the Company’s receipt of consideration, or if the value of outstanding shares of Common Stock is
substantially reduced because of a spinoff or the Company’s payment of an extraordinary dividend or distribution, the Compensation
Committee will equitably adjust the following:
| |
● |
the
maximum number and kind of shares of Common Stock available for issuance under the Second Amended and Restated 2023 Equity
Incentive Plan, |
| |
|
|
| |
● |
the
maximum grant date value of awards that a non-employee director may receive in a year (calculated as described above), |
| |
|
|
| |
● |
the
number and kind of shares of Common Stock issued and to be issued under the Second Amended and Restated 2023 Equity Incentive
Plan, |
| |
|
|
| |
● |
the
price per Share or applicable market value of awards will be equitably adjusted by the Compensation Committee, and |
| |
|
|
| |
● |
exercise
price of options, base amount of SARs, performance goals or other terms and conditions that the Compensation Committee deems appropriate
and subject to the Second Amended and Restated 2023 Equity Incentive Plan’s repricing restrictions. |
The
Compensation Committee will make adjustments to reflect changes in the number, kind, or value or shares of Common Stock issued
to prevent, to the extent possible, the enlargement or dilution of rights and benefits under the Second Amended and Restated 2023 Equity
Incentive Plan and for any outstanding awards, in each case subject to and consistent with applicable law. The Compensation Committee
will eliminate any fractional shares of Common Stock resulting from adjustment.
The
Compensation Committee may also make adjustments to the terms and conditions of outstanding awards in recognition of unusual or nonrecurring
events, including acquisitions and dispositions of business assets, which affect the Company, its subsidiaries or business units, or
any financial statements of the Company or its subsidiaries, or in response to changes in applicable laws, regulations, or accounting
principles. In the event of certain transactions that represent a change in control (as described below), the change in control provisions
of the Second Amended and Restated 2023 Equity Incentive Plan apply.
Lastly,
the Compensation Committee has sole discretion and authority to determine the adjustments to be made, and adjustments by the Compensation
Committee are final, binding, and conclusive.
Eligibility
All
employees and non-employee directors, and certain key advisors (including consultants and advisors of the Company) that provide services
to us and our subsidiaries are eligible to participate in the Second Amended and Restated 2023 Equity Incentive Plan. The Compensation
Committee will select which eligible services providers will receive grants of awards under the Second Amended and Restated 2023 Equity
Incentive Plan. As of November 7, 2024, approximately 127 employees, 8 non-employee directors and various consultants and advisors would
have been eligible to participate in the Second Amended and Restated 2023 Equity Incentive Plan if the Second Amended and Restated 2023
Equity Incentive Plan were in effect on such date.
Vesting
and Minimum Vesting Requirements
The
Compensation Committee determines the vesting and exercisability terms of awards granted under the Second Amended and Restated 2023 Equity
Incentive Plan and such awards will have regular vesting schedules that provide that no portion of an award will vest earlier than one
year from the draft of grant. However, (i) awards granted to non-employee directors will be deemed to satisfy this minimum vesting requirement
if granted on the date of our Special Meeting of stockholders and vest on the date of our Special Meeting of stockholders immediately
following the date of grant (but in any event, not less than 50 weeks), and (ii) up to 5% of the shares of Common Stock reserved
for issuance under the Second Amended and Restated 2023 Equity Incentive Plan as of the Effective Date (subject to adjustment described
above) may be granted without regard to this minimum vesting requirement. The Compensation Committee may accelerate vesting of any award
in its discretion.
Options
Under
our Second Amended and Restated 2023 Equity Incentive Plan, the Compensation Committee may grant incentive stock options and nonqualified
stock options. Incentive stock options may be granted to employees of the Company or any parent or subsidiary of the Company, according
to Section 424 of the Code. Nonqualified stock options may be granted to employees, non-employee directors, and key advisors. The exercise
price of an option granted under the Second Amended and Restated 2023 Equity Incentive Plan will be determined by the Compensation Committee
but cannot be less than the fair market value of a Share on the date the option is granted. If an incentive stock option is granted to
a 10% stockholder, the exercise price cannot be less than 110% of the fair market value of a Share on the date the option is granted.
The
Compensation Committee will determine the term of an option, with a term limit of no more than 10 years from the date of grant. However,
an incentive stock option that is granted to a 10% stockholder, cannot have a term that exceeds five years from the date of grant.
Subject
to the minimum vesting requirements of the Second Amended and Restated 2023 Equity Incentive Plan, options will become exercisable according
to the terms and conditions set by the Compensation Committee in the award agreement. The Compensation Committee may accelerate the exercisability
of any outstanding options at any time and for any reason. The Compensation Committee will determine in the award agreement under what
circumstances and during what time periods a participant may exercise an option after termination of employment or service. Any options
granted to non-exempt employees cannot be exercisable for at least six months after the grant date, except as determined by the Compensation
Committee.
A
participant can exercise an option that has become exercisable by delivering a notice of exercise to the Company. The exercise price
for any option is generally payable in cash or check. In certain circumstances, as permitted by the Compensation Committee, the exercise
price may be paid by the surrender of shares of Common Stock with an aggregate fair market value on the date the option is exercised
equal to the exercise price; by payment through a broker in accordance with procedures established by the Federal Reserve Board; by withholding
shares of Common Stock subject to the exercisable option that have a fair market value on the date of exercise equal to the aggregate
exercise price; or by such other method as the Compensation Committee approves.
Stock
Awards
The
Compensation Committee may grant stock awards of our common stock to anyone eligible under the Second Amended and Restated 2023 Equity
Incentive Plan. Stock awards may be subject to restrictions as the Compensation Committee determines. The restrictions, if any, may lapse
over a specified period or based on the satisfaction of pre-established criteria, as determined by the Compensation Committee, including,
but not limited to, restrictions based on the achievement of performance goals. The award agreement will set the period of time during
which the stock awards will be subject to restrictions, during which time a participant cannot sell, assign, transfer, pledge, or otherwise
dispose of the shares of a stock award, except as permitted by the Compensation Committee.
If
a participant ceases to be employed by or provide services to the Company during any restricted period, or if other specified conditions
are not met, any unvested portion of the stock award will be forfeited, unless the Compensation Committee determines otherwise.
Unless
otherwise determined by the Compensation Committee, a participant will have the right to vote and the right to receive dividends or other
distributions paid on the shares, subject to any restrictions, including the achievement of performance goals, that the Compensation
Committee may determine. Dividends with respect to stock awards will only vest if and to the extent that the underlying stock award vests,
as determined by the Compensation Committee.
Stock
Units
The
Compensation Committee may grant stock units to anyone eligible to participate in the Second Amended and Restated 2023 Equity Incentive
Plan. Stock units represent hypothetical shares of Common Stock, and each represents a right that a participant has to receive
a Share or amount of cash based on the common stock’s value, if and when specified conditions are met.
Stock
units become payable if certain conditions or circumstances are met, including specified performance goals. The Compensation Committee
may accelerate vesting or payment for any reason and at any time, provided that the acceleration complies with Section 409A of the Code.
Payment for stock units can be made in common stock, cash, or any combination of the two as determined by the Compensation Committee.
All unvested stock units are forfeited if the participant’s employment or service is terminated for any reason, unless the Compensation
Committee determines otherwise.
Stock
Appreciation Rights
The
Compensation Committee may grant SARs to anyone eligible for the Second Amended and Restated 2023 Equity Incentive Plan separately or
in tandem with any option. Tandem SARs for non-qualified stock options may be granted at the time an option is granted or while an option
is outstanding. In the case of incentive stock options, SARs may only be granted at the time the incentive stock option is granted. The
Compensation Committee will establish the base amount of the SAR at the time the SAR is granted, which will be equal to or greater than
the fair market value of a share of our common stock as of the date of grant, as well as the vesting and other restrictions applicable
to the exercisability of a SAR.
If
a SAR is granted in tandem with an option, the number of SARs that are exercisable during a specified period will not exceed the number
of shares of Common Stock that the participant may purchase upon exercising the related option during such period. Upon exercising
the related option, the related SARs will terminate, and upon the exercise of a SAR, the related option will terminate to the extent
of an equal number of shares of Common Stock. Generally, SARs may only be exercised while the participant is employed by, or providing
services to, us or during an applicable period following termination. If a SAR is granted to a non-exempt employee, it may not be exercisable
for at least six months after the date of grant.
When
a participant exercises a SAR, the participant will receive the excess of the fair market value of the underlying common stock over the
base amount of the SAR. The appreciation of a SAR will be paid in shares of Common Stock, cash or both.
The
term of any SAR cannot exceed 10 years from the date of grant. In the event that on the last day of the term of a SAR, the exercise is
prohibited by applicable law, including a prohibition on purchases or sales of our common stock under our insider trading policy, the
term of the SAR will be extended for a period of 30 days following the end of the legal prohibition, unless the Compensation Committee
determines otherwise.
Other
Stock-Based Awards
The
Compensation Committee may grant other stock-based awards that are based on or measured by our common stock to anyone who is eligible
to participate in the Second Amended and Restated 2023 Equity Incentive Plan, subject to terms and conditions set by the Compensation
Committee. Other stock-based awards may be subject to the achievement of performance goals or criteria, and may be payable in cash, shares
of Common Stock, or a combination of the two, as determined by the Compensation Committee.
Dividend
Equivalents
The
Compensation Committee may grant dividend equivalents in connection with stock units or other stock-based awards, either in the award
agreement or at any point following the grant of the stock unit or other stock-based award. Dividends and dividend equivalents granted
in connection with an award of stock units or other stock-based award will vest and be paid only if and to the extent that the underlying
award of stock units or other stock-based award is vested and paid. Dividend equivalents may be payable in cash or shares of Common
Stock and upon terms and conditions set by the Compensation Committee.
Dividends
and dividend equivalents may not be granted in connections with options or SARs.
Prohibition
on Repricing
Except
in connection with a corporate transaction involving the Company, the Compensation Committee may not (i) amend the terms of any outstanding
stock options or SARs to reduce the exercise price or base price, as applicable; (ii) cancel outstanding stock options or SARs in exchange
for stock options or SARs with an exercise price or base price that is lower than the exercise price or base price of the original option
or SAR; or (iii) cancel outstanding stock options or SARs with an exercise price or base price, as applicable, above the current stock
price in exchange for cash or other securities.
Change
in Control
If
we experience a change in control where we are not the surviving corporation (or survive only as a subsidiary of another corporation),
unless the Compensation Committee determines otherwise, all outstanding grants that are not exercised, unvested or paid at the time of
the change in control will be assumed by or replaced with grants (with respect to cash, securities or a combination thereof) that have
comparable terms by the surviving corporation (or a parent or subsidiary of the surviving corporation).
Unless
the Compensation Committee or applicable award agreement provides otherwise, if a participant’s employment or service to the Company
is terminated involuntarily upon or within 12 months following a change in control, the participant’s awards become fully vested
as of the date of such termination. For awards that become vested based, in whole or in part, on performance, the applicable award agreement
must specify how to calculate the portion of such grant that becomes vested.
If
there is a change in control and all outstanding grants are not assumed by or replaced with grants that have comparable terms by the
surviving company, then the Compensation Committee may (but is not required to) adjust the terms and conditions of outstanding awards,
including, without limitation, taking any of the following actions (or combination thereof) without the consent of any participant:
| ● |
determine
that outstanding options and SARs will automatically accelerate and become fully exercisable and the restrictions and conditions
on outstanding stock awards, stock units, other stock-based awards, and dividend equivalents immediately lapse; |
| ● |
determine
that participants will receive payment, in an amount and form determined by the Compensation Committee, in settlement of outstanding
stock units, other stock-based awards, or dividend equivalents; |
| |
|
| ● |
require
that participants surrender their outstanding stock options and SARs in exchange for a payment by the Company, in cash or shares
of Common Stock, equal to the difference between the exercise price and the fair market value of the underlying shares;
provided, however, if the per Share fair market value of our common stock does not exceed the per Share stock option exercise price
or SAR base amount, as applicable, we will not be required to make any payment to the participant upon surrender of the stock option
or SAR; or |
| |
|
| ● |
after
giving participants an opportunity to exercise all of their outstanding stock options and SARs, terminate any unexercised stock options
and SARs on the date determined by the Compensation Committee. |
In
general terms, a change in control under the Second Amended and Restated 2023 Equity Incentive Plan occurs if:
| ● |
the
consummation of a transaction where a person, entity or affiliated group, with certain exceptions, acquires more than 50% of our
then-outstanding voting securities; |
| |
|
| ● |
we
merge into another entity unless the holders of our voting shares immediately prior to the merger have at least 50% of the combined
voting power of the securities in the merged entity or its parent; |
| |
|
| ● |
we
merge into another entity and the members of our Board prior to the merger would not constitute a majority of the board of the merged
entity or its parent; |
| |
|
| ● |
we
sell or dispose of all or substantially all of our assets; |
| |
|
| ● |
we
consummate a complete liquidation or dissolution; or |
| |
|
| ● |
a
majority of the members of our Board is replaced during any 12-month period by directors whose appointment or election is not endorsed
by a majority of the incumbent directors. |
Deferrals
The
Compensation Committee may permit or require participants to defer receipt of the payment of cash or the delivery of shares of Common
Stock that would otherwise be due to the participant in connection with a grant under the Second Amended and Restated 2023 Equity
Incentive Plan. The Compensation Committee will establish the rules and procedures applicable to any such deferrals, consistent with
the requirements of Section 409A of the Code.
Valuation
The
fair market value per Share on any relevant date under the Second Amended and Restated 2023 Equity Incentive Plan will be deemed to be
equal to the closing sale price per Share during regular hours trading on the relevant date on Nasdaq (or any other national securities
exchange on which our Common Stock is at the time primarily traded). If there is no closing selling price for Common Stock on the date
in question, then the fair market value shall be the last reported sale price during regular trading hours on the last preceding date
for which a sale was reported. On November 7, 2024, the fair market value per Share of our Common Stock was $6.38.
Withholding
All
awards under the Second Amended and Restated 2023 Equity Incentive Plan are subject to applicable U.S. federal (including FICA), state
and local, foreign or other tax withholding requirements. We may require participants or other persons receiving or exercising awards
to pay an amount sufficient to satisfy such tax withholding requirements with respect to such awards, or we may deduct from other wages
and compensation paid by us the amount of any withholding taxes due with respect to such grant. We may also take any other actions that
the Compensation Committee deems advisable to enable us to satisfy our withholding tax and other tax obligations with respect to any
award made under the Second Amended and Restated 2023 Equity Incentive Plan.
The
Compensation Committee may permit or require that our tax withholding obligation with respect to awards paid in our common stock be paid
by having shares of Common Stock withheld up to an amount that does not exceed the participant’s minimum applicable withholding
tax rate for U.S. federal (including FICA), state and local tax liabilities, or as otherwise determined by the Compensation Committee.
In addition, the Compensation Committee may, in its discretion, and subject to such rules as the Compensation Committee may adopt, allow
participants to elect to have such share withholding applied to all or a portion of the tax withholding obligation arising in connection
with any particular grant.
Transferability
Except
as permitted by the Compensation Committee with respect to non-qualified stock options, only a participant may exercise rights under
a grant during the participant’s lifetime. A participant cannot transfer those rights except by will or by the laws of descent
and distribution or, with respect to awards other than incentive stock options, pursuant to a domestic relations order. Upon death, the
personal representative or other person entitled to succeed to the rights of the participant may exercise such rights. The Compensation
Committee may provide in an award agreement that a participant may transfer non-qualified stock options and stock awards to family members,
or one or more trusts or other entities for the benefit of or owned by family members, consistent with applicable securities laws.
Amendment;
Termination
The
Board may amend or terminate the Second Amended and Restated 2023 Equity Incentive Plan at any time, except that the Board must receive
stockholder approval to do so if required to comply with the Code, applicable law, or applicable stock exchange requirements.
The
Second Amended and Restated 2023 Equity Incentive Plan will terminate on the day immediately preceding the 10th anniversary of its Effective
Date, unless terminated earlier by the Board or unless the Board, with stockholder approval, extends the term of the Second Amended and
Restated 2023 Equity Incentive Plan.
If
a termination or amendment occurs after an award is made, it will not materially impair the rights of a participant with respect to the
award, unless the participant consents or the Compensation Committee acts in compliance with applicable law or other exceptions set forth
in the Second Amended and Restated 2023 Equity Incentive Plan.
Establishment
of Sub-Plans
Our
Board may from time to time establish one or more sub-plans under the Second Amended and Restated 2023 Equity Incentive Plan to satisfy
applicable blue sky, securities or tax laws of various jurisdiction. The Board will establish sub-plans by setting forth the Compensation
Committee’s discretionary limits under the Second Amended and Restated 2023 Equity Incentive Plan and any additional terms and
conditions not otherwise inconsistent with the Second Amended and Restated 2023 Equity Incentive Plan.
Clawback
All
grants of awards under the Second Amended and Restated 2023 Equity Incentive Plan will be subject to any applicable clawback or recoupment
policies, share trading policies, and other policies that the Board or Compensation Committee may implement or approve at any time. We
may offset any payments due under the Second Amended and Restated 2023 Equity Incentive Plan to a participant where repayment is required
by an applicable clawback or recoupment policy, subject to applicable law.
Subject
to applicable law, the Compensation Committee may provide in any award agreement that if a participant breaches any restrictive covenant
obligation or agreement between the participant and us, or otherwise engages in activities that constitute misconduct either while employed
by, or providing services to, us or within a specified period thereafter, all awards held by the participant will terminate, and we may
rescind any exercise of an option or SAR and the vesting of any other award and delivery of shares of Common Stock upon such exercise
or vesting, as applicable on such terms as the Compensation Committee will determine, including the right to require that in the event
of any rescission:
| ● |
the
participant must return the shares of Common Stock received upon the exercise of any option or SAR or the vesting and payment
of any other grants; or |
| |
|
| ● |
if
the participant no longer owns the shares of Common Stock , the participant must pay to us the amount of any gain realized
or payment received as a result of any sale or other disposition of the shares of Common Stock (if the participant transferred
the shares of Common Stock by gift or without consideration, then the fair market value of the shares of Common Stock
on the date of the breach of the restrictive covenant agreement or activity constituting cause), net of the price originally paid
by the participant for the shares. |
Payment
by the participant will be made in such manner and on such terms and conditions as may be required by the Compensation Committee. We
will be entitled to set off against the amount of any such payment any amounts that we otherwise owe to the participant.
Certain
Federal Income Tax Aspects
The
following is a summary of certain federal income tax consequences of awards under the Second Amended and Restated 2023 Equity Incentive
Plan. It does not purport to be a complete description of all applicable rules, and those rules (including those summarized here) are
subject to change.
Options
An
optionee generally will not recognize taxable income upon the grant of a non-statutory option. Rather, at the time of exercise of the
option, the optionee will recognize ordinary income for income tax purposes in an amount equal to the excess, if any, of the fair market
value of the shares of Common Stock purchased over the exercise price. We generally will be entitled to a tax deduction at such
time and in the same amount, if any, that the optionee recognizes as ordinary income. The optionee’s tax basis in any shares
of Common Stock received upon the exercise of an option will be the fair market value of the shares of Common Stock on the
date of exercise, and if the shares of Common Stock are later sold or exchanged, then the difference between the amount received
upon such sale or exchange and the fair market value of such shares of Common Stock on the date of exercise will generally be
taxable as long-term or short-term capital gain or loss (if the shares of Common Stock are a capital asset of the optionee) depending
upon the length of time such shares of Common Stock were held by the optionee.
Incentive
stock options are eligible for favorable U.S. federal income tax treatment if certain requirements are satisfied. An incentive stock
option must have an option price that is not less than the fair market value of the stock at the time the option is granted and must
be exercisable within 10 years from the date of grant. An employee granted an incentive stock option generally does not realize compensation
income for U.S. federal income tax purposes upon the grant of the option. At the time of exercise of an incentive stock option, no compensation
income is realized by the optionee other than tax preference income for purposes of the federal alternative minimum tax on individual
income. If the shares of Common Stock acquired on exercise of an incentive stock option are held for at least two years after
grant of the option and one year after exercise, the excess of the amount realized on the sale over the exercise price will be taxed
as capital gain. If the shares of Common Stock acquired on exercise of an incentive stock option are disposed of within less than
two years after grant or one year of exercise, the optionee will realize taxable compensation income equal to the lesser of (i) the excess
of the fair market value of the shares of Common Stock on the date of exercise over the option price or (ii) the excess of the
amount realized on the sale over the option price. Any additional amount realized will be taxed as capital gain.
Stock
Awards
A
participant generally will not be taxed upon the grant of stock awards subject to restrictions, but rather will recognize ordinary income
in an amount equal to the fair market value of the shares of Common Stock at the time the shares of Common Stock are no
longer subject to a “substantial risk of forfeiture” (within the meaning of the Code). We generally will be entitled to a
deduction at the time when, and in the amount that, the participant recognizes ordinary income on account of the lapse of the restrictions.
A participant’s tax basis in the shares of Common Stock will equal their fair market value at the time the restrictions
lapse, and the participant’s holding period for capital gains purposes will begin at that time. Any cash dividends paid on the
restricted stock before the restrictions lapse will be taxable to the participant as additional compensation (and not as dividend income).
Under Section 83(b) of the Code, a participant may elect to recognize ordinary income at the time the shares of Common Stock of
stock are awarded in an amount equal to their fair market value at that time, notwithstanding the fact that such shares of Common
Stock of stock are subject to restrictions and a substantial risk of forfeiture. If such an election is made, no additional taxable
income will be recognized by such participant at the time the restrictions lapse, the participant will have a tax basis in the shares
of Common Stock equal to their fair market value on the date of their award, and the participant’s holding period for capital
gains purposes will begin at that time. We generally will be entitled to a tax deduction at the time when, and to the extent that, ordinary
income is recognized by such participant.
Stock
Units
In
general, the grant of stock units will not result in income for the participant or in a tax deduction for us. Upon the settlement of
such an award in cash or shares, the participant will recognize ordinary income equal to the aggregate value of the payment received,
and we generally will be entitled to a tax deduction at the same time and in the same amount.
Stock
Appreciation Rights
A
participant who is granted a SAR generally will not recognize ordinary income upon receipt of the SAR. Rather, at the time of exercise
of such SAR, the participant will recognize ordinary income for U.S. federal income tax purposes in an amount equal to the value of any
cash received and the fair market value on the date of exercise of any shares of Common Stock received. We generally will be entitled
to a tax deduction at such time and in the same amount, if any, that the participant recognizes as ordinary income. The participant’s
tax basis in any shares of Common Stock received upon exercise of a SAR will be the fair market value of the shares of Common
Stock on the date of exercise, and if the shares of Common Stock are later sold or exchanged, then the difference between
the amount received upon such sale or exchange and the fair market value of such shares of Common Stock on the date of exercise
will generally be taxable as long-term or short-term capital gain or loss (if the shares of Common Stock are a capital asset of
the participant) depending upon the length of time such shares of Common Stock were held by the participant.
Other
Stock-Based Awards
With
respect to other stock-based awards granted under the Second Amended and Restated 2023 Equity Incentive Plan, generally when the participant
receives payment with respect to an award, the amount of cash and/or the fair market value of any shares of Common Stock or other
property received will be ordinary income to the participant, and we generally will be entitled to a tax deduction at the same time and
in the same amount.
Impact
of Section 409A
Section
409A of the Code applies to deferred compensation, which is generally defined as compensation earned currently, the payment of which
is deferred to a later taxable year. Awards under the Second Amended and Restated 2023 Equity Incentive Plan are intended to be exempt
from the requirements of Section 409A or to satisfy its requirements. An award that is subject to Section 409A and fails to satisfy its
requirements will subject the holder of the award to immediate taxation, interest and an additional 20% tax on the vested amount underlying
the award.
Section
162(m) of the Code
Section
162(m) of the Code generally disallows a tax deduction to a publicly held company for compensation in excess of $1 million paid to its
“covered employees” which generally includes all NEOs. While the Compensation Committee considers the tax deductibility of
each element of executive compensation as a factor in our overall compensation program, the Compensation Committee retains the discretion
to approve compensation that may not qualify for the compensation deduction.
New
Plan Benefits
Future
benefits under the Second Amended and Restated 2023 Equity Incentive Plan generally will be granted at the discretion of the Compensation
Committee and are therefore not currently determinable.
Because
future grants of awards under the Second Amended and Restated 2023 Equity Incentive Plan, if approved, would be subject to the discretion
of the Board or Compensation Committee, the amount and terms of future awards to particular participants or groups of participants are
not determinable at this time. No awards have been previously granted that are contingent on the approval of the Second Amended and Restated
2023 Equity Incentive Plan.
Proposal
1 will be approved upon the affirmative vote of a majority of the outstanding shares of Common Stock present through virtual attendance
or by proxy at the Special Meeting and entitled to vote on the proposal. Stockholders may vote “FOR” or “AGAINST,”
or “ABSTAIN” from voting. Abstentions will have the effect of a vote “AGAINST” this proposal.
Required
Vote
Proposal
1 will be approved on an advisory basis upon the affirmative vote of a majority of the outstanding shares of Common Stock present in
person or by proxy at the Special Meeting and entitled to vote on such proposal. Stockholders may vote “FOR” or “AGAINST,”
or “ABSTAIN” from voting. Abstentions will have the effect of a vote “AGAINST” this proposal.
Recommendation
of the Board
The
Board recommends that the stockholders vote “FOR” the approval of the Second Amended and Restated 2023 Equity Incentive Plan
as set forth in this Proxy Statement for the Special Meeting
PROPOSAL
2
APPROVAL
OF POSSIBLE ADJOURNMENT OF THE SPECIAL MEETING
The
Board believes that if there are insufficient votes to approve Proposal No. 1, it is in the best interests of the stockholders to enable
the Board to continue to seek to obtain a sufficient number of additional votes to approve Proposal No. 1.
If
we fail to receive a sufficient number of votes to approve Proposal No. 1, we may propose to adjourn the Special Meeting, for a period
of not more than 60 days, for the purpose of soliciting additional proxies to approve Proposal No. 1. The Company currently does not
intend to propose an adjournment at the Special Meeting if there are sufficient votes to approve Proposal No. 1.
Required
Vote
Proposal
2 will be approved on an advisory basis upon the affirmative vote of a majority of the outstanding shares of Common Stock present in
person or by proxy at the Special Meeting and entitled to vote on such proposal. Stockholders may vote “FOR” or “AGAINST,”
or “ABSTAIN” from voting. Abstentions will have the effect of a vote “AGAINST” this proposal.
Recommendation
of the Board
The
Board recommends that the stockholders vote “FOR” the approval to adjourn the Special Meeting, if necessary, to solicit additional
proxies if there are not sufficient votes in favor of Proposal No. 1
OTHER
MATTERS
As
of the date of this proxy statement, the Board is not aware of any matters to be presented for consideration at the Special Meeting other
than those referred to above. If (i) any matters not within the knowledge of the Board as of the date of this proxy statement should
properly come before the Special Meeting; (ii) any proposals properly omitted from this proxy statement and the form of proxy, subject
to applicable laws and our Certificate of Incorporation and Bylaws, should come before the Special Meeting; or (iii) any matters should
arise incident to the conduct of the Special Meeting, then the proxies will be voted by the persons named in the enclosed form of proxy,
or their substitutes acting thereunder, in accordance with the recommendations of the Board, or, if no such recommendations are made,
in accordance with their best judgment.
STOCKHOLDERS
SHARING AN ADDRESS OR HOUSEHOLD
Only
one copy of our Proxy Statement is being delivered to multiple stockholders sharing an address unless we have received instructions to
the contrary from one or more of the stockholders.
We
will deliver promptly upon written or oral request a separate copy of our Proxy Statement to any stockholder at a shared address to which
a single copy of any of those documents was delivered. To receive a separate copy of our Proxy Statement, or if two stockholders sharing
an address have received two copies of any of these documents and desire to only receive one, you may write to the Company at c/o Investor
Relations, 6555 Carnegie Ave., 4th Floor, Cleveland, OH 44103 or call the Company at 646-813-4701.
COST
AND METHOD OF SOLICITATION
We
will pay the cost of soliciting proxies. Proxies may be solicited on behalf of the Company by directors, officers or employees of Abeona
in person or by telephone, email or other electronic means. As required by the SEC, we also will reimburse brokerage firms and other
custodians, nominees and fiduciaries for their expenses incurred in sending proxies and proxy materials to beneficial owners of our Common
Stock.
WHERE
YOU CAN FIND ADDITIONAL INFORMATION
We
make available free of charge through our website, www.abeonatherapeutics.com, our annual reports on Form 10-K and other reports that
we file with the SEC as well as certain of our corporate governance policies, including the charters for the audit, compensation and
nominating and corporate governance committees of the Board and our code of ethics, corporate governance guidelines and whistleblower
policy. We will also provide to any person without charge, upon request, a copy of any of the foregoing materials. Any such request must
be made in writing to us at: Abeona Therapeutics Inc. c/o Investor Relations, 6555 Carnegie Ave., 4th Floor, Cleveland, OH
44103 and is also available on our website at www.abeonatherapeutics.com under the heading “Investors & Media—SEC Filings.”
The SEC’s website, www.sec.gov, contains reports, proxy statements, and other information that we file electronically with the
SEC. The content on any website referred to in this proxy statement is not incorporated by reference in this proxy statement unless expressly
noted.
APPENDIX
A
SECOND
Amended and Restated Abeona Therapeutics Inc. 2023 Equity Incentive Plan
Section
1. Effectiveness and Purpose.
Effective
as of the date this plan is approved by the Corporation’s stockholders, the Second Amended and Restated Abeona Therapeutics
Inc. 2023 Equity Incentive Plan (as may be amended from time to time, the “Plan”) is hereby established.
The Plan was initially approved
by the Corporation’s stockholders on the Effective Date, and was first amended and restated to increase the number of shares of
Common Stock reserved for issuance thereunder as approved by the Corporation’s stockholders on April 24, 2024. The Plan was further
amended and restated in its present form on November 1, 2024, which is the date on which the amendment and restatement of the Plan in
its present form was approved by the Board (the “Restatement Date”), subject to approval by the Corporation’s
stockholders. The terms of the Plan as amended and restated herein shall apply to all Awards granted under the Plan prior to, on or following
the Restatement Date. If this amendment and restatement of the Plan is not approved by the Company’s stockholders at the Corporation’s
2024 Special Meeting of Stockholders, then this amendment and restatement of the Plan will be null and void in its entirety and the Plan
as approved by the Corporation’s stockholders on April 24, 2024 will remain in effect.
The
purpose of the Plan is to provide employees of Abeona Therapeutics Inc., a Delaware corporation (together with its successors, the “Corporation”),
and its Subsidiaries, certain consultants and advisors who perform services for the Corporation or its Subsidiaries, and non-employee
members of the Board, with the opportunity to receive grants of equity awards in the form of incentive stock options, nonqualified stock
options, stock appreciation rights, stock awards, stock units, and other stock-based awards. Capitalized terms used in the Plan and not
otherwise defined herein shall have the meaning assigned to them in Section 2.
The
Corporation believes that the Plan will encourage the participants to contribute materially to the growth of the Corporation, thereby
benefitting the Corporation’s stockholders, and will align the economic interests of the participants with those of the stockholders.
The
Plan is intended to replace the Prior Plan. No additional grants shall be made under the Prior Plan on or after the Effective Date. Outstanding
grants under the Prior Plan shall continue in effect according to their terms.
Section
2. Definitions.
The
following terms shall have the meanings set forth below for purposes of the Plan:
(a)
“Affiliate” means, when used with reference to any Person, any other Person that directly or indirectly, through
one or more intermediaries, controls, is controlled by or is under common control with, or owns greater than 50% of the voting power
in, the specified Person (the term “control” for this purpose means the ability, whether by the ownership of shares or other
equity interest, by contract or otherwise, to elect a majority of the directors of a corporation, independently to select the managing
partner of a partnership or the managing member or the majority of the managers, as applicable, of a limited liability company, or otherwise
to have the power independently to remove and then select a majority of those Persons exercising governing authority over an entity,
and control shall be conclusively presumed in the case of the direct or indirect ownership of 50% or more of the voting equity interests
in the specified Person).
(b)
“Award” means an Option, SAR, Stock Award, Stock Unit or Other Stock-Based Award granted under the Plan.
(c)
“Award Agreement” means the written agreement that sets forth the terms and conditions of an Award, including
all amendments thereto.
(d)
“Board” means the Board of Directors of the Corporation.
(e)
“CEO” means the Chief Executive Officer of the Corporation.
(f)
“Change in Control” means a change in ownership or control of the Corporation effected through any of the following
transactions:
(i)
any “person” (as such term is used in sections 13(d) and 14(d) of the Exchange Act) becomes a “beneficial owner”
(as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Corporation representing more than fifty
percent (50%) of the voting power of the then-outstanding securities of the Corporation; provided that a Change in Control shall
not be deemed to occur as a result of a transaction in which the Corporation becomes a direct or indirect subsidiary of another Person
and in which the stockholders of the Corporation, immediately prior to the transaction, will beneficially own, immediately after the
transaction, shares of such other Person representing more than fifty percent (50%) of the voting power of the then-outstanding securities
of such other Person;
(ii)
the consummation of (A) a merger or consolidation of the Corporation with another Person where, immediately after the merger or consolidation,
the stockholders of the Corporation, immediately prior to the merger or consolidation, will not beneficially own, in substantially the
same proportion as ownership immediately prior to the merger or consolidation, shares entitling such stockholders to more than fifty
percent (50%) of all votes to which all stockholders of the surviving Person would be entitled in the election of directors, or where
the members of the Board, immediately prior to the merger or consolidation, will not, immediately after the merger or consolidation,
constitute a majority of the board of directors of the surviving Person or (B) a sale or other disposition of all or substantially all
of the assets of the Corporation;
(iii)
a change in the composition of the Board over a period of twelve (12) consecutive months or less such that a majority of the Board members
ceases, by reason of one or more contested elections, or threatened election contests, for Board membership, to be comprised of individuals
who either (A) have been Board members continuously since the beginning of such period or (B) have been elected or nominated for election
as Board members during such period by at least a majority of the Board members described in clause (A) who were still in office at the
time the Board approved such election or nomination; or
(iv)
the consummation of a complete dissolution or liquidation of the Corporation.
The
Committee may modify the definition of Change in Control for a particular Award as the Committee deems appropriate to comply with Section
409A of the Code. Notwithstanding the foregoing, if an Award constitutes deferred compensation subject to Section 409A of the Code and
the Award provides for payment upon a Change in Control, then, for purposes of such payment provisions, no Change in Control shall be
deemed to have occurred upon an event described in items (i)-(iv) above unless the event would also constitute a change in ownership
or effective control of, or a change in the ownership of a substantial portion of the assets of, the Corporation under Section 409A of
the Code.
(g)
“Code” means the Internal Revenue Code of 1986, as amended, and the regulations promulgated thereunder.
(h)
“Committee” means the Compensation Committee of the Board or another committee appointed by the Board to administer
the Plan. The Committee shall consist of directors who are “non-employee directors” as defined under Rule 16b-3 promulgated
under the Exchange Act and “independent directors,” as determined in accordance with the independence standards established
by the stock exchange on which the Common Stock is at the time primarily traded.
(i)
“Common Stock” means common stock, par value $.01 per share, of the Corporation, and such other securities
as may be substituted for Common Stock pursuant to Section 5(c) or Section 5(e).
(j)
“Disability” or “Disabled” has the meaning set forth in an applicable Award Agreement
or employment or services agreement with a Participant, and in the absence of the forgoing, means (i) the Participant’s becoming
disabled within the meaning of the Employer’s long-term disability plan applicable to the Participant, or (ii) if no long-term
disability plan is applicable to the Participant, the Participant’s inability to engage in any substantial gainful activity by
reason of any medically determinable physical or mental impairment that is expected to result in death or has lasted or can be expected
to last for a continuous period of six months or more.
(k)
“Dividend Equivalent” means an amount determined by multiplying the number of shares of Common Stock subject
to a Stock Unit or Other Stock-Based Award by the per-share cash dividend paid by the Corporation on its outstanding Common Stock, or
the per-share Fair Market Value of any dividend paid on its outstanding Common Stock in consideration other than cash. If interest is
credited on accumulated divided equivalents, the term “Dividend Equivalent” shall include the accrued interest.
(l)
“Effective Date” means May 17, 2023.
(m)
“Employed by, or providing service to, the Employer” means employment or service as an Employee, Key Advisor
or member of the Board (so that, for purposes of exercising Options and SARs and satisfying conditions with respect to Stock Awards,
Stock Units, and Other Stock-Based Awards, a Participant shall not be considered to have terminated employment or service until the Participant
ceases to be an Employee, Key Advisor and member of the Board), unless the Committee determines otherwise. If a Participant’s relationship
is with a Subsidiary and that entity ceases to be a Subsidiary, the Participant will be deemed to cease employment or service when the
entity ceases to be a Subsidiary, unless the Participant transfers employment or service to an Employer. If a Participant has military,
sick leave or other bona fide leave, the Participant will not be deemed to cease employment or service solely as a result of such leave;
provided that such leave does not exceed the longer of 90 days or the period during which the absent Participant’s reemployment
rights, if any, are guaranteed by statute or contract. To the extent consistent with applicable law, the Committee may provide that Awards
continue to vest for all or a portion of the period of such leave, or that vesting shall be tolled during such leave and only recommence
upon the Participant’s return from such leave.
(n)
“Employee” means an employee of the Employer (including an officer or director who is also an employee), but
excluding any person who is classified by the Employer as a “contractor” or “consultant,” no matter how characterized
by the Internal Revenue Service, other governmental agency or a court. Any change of characterization of an individual by the Internal
Revenue Service or any court or government agency shall have no effect upon the classification of an individual as an Employee for purposes
of this Plan, unless the Committee determines otherwise.
(o)
“Employer” means the Corporation and its Subsidiaries.
(p)
“Exchange Act” means the Securities Exchange Act of 1934, as amended.
(q)
“Exercise Price” means the per share price at which shares of Common Stock may be purchased under an Option,
as designated by the Committee.
(r)
“Fair Market Value” means:
(i)
If the Common Stock is publicly traded, the Fair Market Value per share shall be determined as follows: (A) if the principal trading
market for the Common Stock is a national securities exchange, the closing sales price during regular trading hours on the relevant date
or, if there were no trades on that date, the latest preceding date upon which a sale was reported, or (B) if the Common Stock is not
principally traded on any such exchange, the last reported sale price of a share of Common Stock during regular trading hours on the
relevant date, as reported by the OTC Bulletin Board.
(ii)
If the Common Stock is not publicly traded or, if publicly traded, is not subject to reported transactions as set forth above, the Fair
Market Value per share shall be determined by the Committee through any reasonable valuation method authorized under the Code.
(s)
“Incentive Stock Option” means an Option that is intended to meet the requirements of an incentive stock option
under Section 422 of the Code.
(t)
“Involuntary Termination” has the following meaning with respect to each Award made under the Plan:
(i)
Involuntary Termination shall have the meaning assigned to such term in the Award Agreement for the particular Award or in any other
agreement incorporated by reference into the Award Agreement for purposes of defining such term.
(ii)
In the absence of any other Involuntary Termination definition in the Award Agreement (or in any other agreement incorporated by reference
into the Award Agreement), Involuntary Termination means such individual’s involuntary dismissal or discharge by the Employer for
reasons other than Misconduct.
(u)
“Key Advisor” means a consultant or advisor of the Employer.
(v)
“Misconduct” has the following meaning with respect to each Award made under the Plan:
(i)
Misconduct shall have the meaning assigned to such term in the Award Agreement for the particular Award or in any other agreement incorporated
by reference into the Award Agreement for purposes of defining such term.
(ii)
In the absence of any other Misconduct definition in the Award Agreement for a particular Award (or in any other agreement incorporated
by reference into the Award Agreement), Misconduct means the commission of any act of fraud, embezzlement or dishonesty by the Participant,
any unauthorized use or disclosure by such person of confidential information or trade secrets of the Corporation or any Affiliate, or
any other intentional misconduct by such person adversely affecting the business or affairs of the Corporation or any Affiliate in a
material manner. The foregoing definition shall not in any way preclude or restrict the right of the Employer to discharge or dismiss
any Participant, employee or other person in the service of the Employer for any other acts or omissions, but such other acts or omissions
shall not be deemed, for purposes of the Plan, to constitute grounds for termination for Misconduct.
(w)
“Non-Employee Director” means a member of the Board who is not an Employee.
(x)
“Nonqualified Stock Option” means an Option that is not intended to be taxed as an incentive stock option under
Section 422 of the Code.
(y)
“Option” means an option to purchase shares of Common Stock, as described in Section 7.
(z)
“Other Stock-Based Award” means any Award based on, measured by or payable in Common Stock (other than an Option,
Stock Unit, Stock Award, or SAR), as described in Section 11.
(aa)
“Participant” means an Employee, Key Advisor or Non-Employee Director designated by the Committee to participate
in the Plan.
(bb)
“Performance Goals” means the business criteria selected by the Corporation to measure the level of performance
of the Corporation or an Affiliate during a performance period, which may include, but are not limited to, one or more of the following
criteria: (i) cash flow; (ii) earnings (including earnings before interest and taxes, earnings before taxes, earnings before interest,
taxes, depreciation, amortization and charges for stock-based compensation, earnings before interest, taxes, depreciation and amortization,
and net earnings); (iii) earnings per share; (iv) growth in earnings or earnings per share; (v) stock price; (vi) return on equity or
average stockholder equity; (vii) total stockholder return or growth in total stockholder return either directly or in relation to a
comparative group; (viii) return on capital; (ix) return on assets or net assets; (x) invested capital, required rate of return on capital
or return on invested capital; (xi) revenue, growth in revenue or return on sales; (xii) income or net income; (xiii) operating income,
net operating income or net operating income after tax; (xiv) operating profit or net operating profit; (xv) operating margin or gross
margin; (xvi) return on operating revenue or return on operating profit; (xvii) market share; (xviii) market capitalization; (xix) application
approvals; (xx) litigation and regulatory resolution goals; (xxi) product sales or milestones; (xxii) budget comparisons; (xxiii) growth
in stockholder value relative to the growth of a peer group or index; (xxiv) development and implementation of strategic plans and/or
organizational restructuring goals; (xxv) development and implementation of risk and crisis management programs; (xxvi) improvement in
workforce diversity; (xxvii) compliance requirements and compliance relief; (xxviii) productivity goals; (xxix) workforce management
and succession planning goals; (xxx) economic value added (including typical adjustments consistently applied from generally accepted
accounting principles required to determine economic value added performance measures); (xxxi) measures of customer satisfaction, employee
satisfaction or staff development; (xxxii) development or marketing collaborations, formations of joint ventures or partnerships or the
completion of other similar transactions intended to enhance the Corporation’s revenue or profitability or enhance its customer
base; (xxxiii) merger and acquisitions; (xxxiv) strategic goals or objectives (including objectives related to qualitative or quantitative
environmental, social or governance metrics); and (xxxiv) other applicable criteria as determined by the Committee. Performance Goals
applicable to an Award shall be determined by the Committee, and may be established on an absolute or relative basis and may be established
on a corporate-wide basis or with respect to one or more business units, divisions, subsidiaries or business segments. Relative performance
may be measured against a group of peer companies, a financial market index or other objective and quantifiable indices.
(cc)
“Person” means any natural person, corporation, limited liability company, partnership, trust, joint stock
company, business trust, unincorporated association, joint venture, governmental authority or other legal entity of any nature whatsoever.
(dd)
“Prior Plan” means the Abeona Therapeutics, Inc. 2015 Equity Incentive Plan, as amended through the Effective
Date.
(ee)
“SAR” means a stock appreciation right, as described in Section 10.
(ff)
“Stock Award” means an award of Common Stock, as described in Section 8.
(gg)
“Stock Unit” means an award of a contractual right to receive one or more shares of Common Stock, cash or combination
thereof, as described in Section 9, and denominated in a number of shares of Common Stock specified in an Award Agreement.
(hh)
“Subsidiary” means any corporation (other than the Corporation) in an unbroken chain of corporations beginning
with the Corporation, provided each corporation (other than the last corporation) in the unbroken chain owns, at the time of the determination,
stock possessing 50% or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.
Section
3. Administration.
(a)
Committee. The Plan shall be administered and interpreted by the Committee; provided, however, that any Awards to members
of the Board must be authorized by a majority of the Board. The Committee may delegate authority to one or more subcommittees of the
Committee or as set forth in Section 3(b), as it deems appropriate. Subject to compliance with applicable law and the applicable stock
exchange rules, the Board, in its discretion, may perform any action of the Committee hereunder. To the extent that the Board, the Committee,
a subcommittee or the CEO, as described below administers the Plan, references in the Plan to the “Committee” shall be deemed
to refer to the Board, the Committee, or such subcommittee or the CEO.
(b)
Delegation to CEO or CFO. Subject to compliance with applicable law and applicable stock exchange requirements, the Committee
may delegate all or part of its authority and power to the CEO or CFO of the Corporation or a committee comprised of executives of the
Corporation, as it deems appropriate, with respect to Awards to Employees or Key Advisors who are not executive officers or directors
under Section 16 of the Exchange Act.
(c)
Committee Authority. The Committee shall have the sole authority to (i) determine the individuals to whom Awards shall be made
under the Plan; (ii) determine the type, size, terms and conditions of the Awards to be made to each such individual; (iii) determine
the time when the Awards will be made and the duration of any applicable exercise or restriction period, including the criteria for exercisability
and the acceleration of exercisability, which criteria may be based on the attainment of Performance Goals; (iv) determine the amounts
payable based on attainment of Performance Goals, including discretion to make such adjustments (positive or negative) to the amounts
payable as the Committee deems appropriate and in the best interests of the Corporation; (v) amend the terms of any previously issued
Award, subject to the provisions of Section 18 below; (vi) determine and adopt terms, guidelines, and provisions, not inconsistent with
the Plan and applicable law, that apply to individuals residing outside of the United States who receive Awards under the Plan; and (vii)
deal with any other matters arising under the Plan.
(d)
Committee Determinations. The Committee shall have full power and express discretionary authority to administer and interpret
the Plan, to make factual determinations and to adopt or amend such rules, regulations, agreements and instruments for implementing the
Plan and for the conduct of its business as it deems necessary or advisable, in its sole discretion. The Committee’s written interpretations
of the Plan and all determinations made by the Committee pursuant to the powers vested in it hereunder shall be conclusive and binding
on all persons having any interest in the Plan or in any Awards granted hereunder. The Committee may rely on internal or external advisors
in determining appropriate interpretations of the Plan or Awards granted hereunder. All powers of the Committee shall be executed in
its sole discretion, in the best interest of the Corporation, not as a fiduciary, and in keeping with the objectives of the Plan and
need not be uniform as to similarly situated individuals.
(e)
Indemnification. No member of the Committee or the Board, and no employee of the Corporation or any Affiliate shall be liable
for any act or failure to act with respect to the Plan, except in circumstances involving such person’s bad faith or willful misconduct,
or for any act or failure to act hereunder by any other member of the Committee or employee or by any agent to whom duties in connection
with the administration of this Plan have been delegated. The Corporation shall indemnify members of the Committee and the Board and
any agent of the Committee or the Board who is an employee of the Corporation or a Subsidiary against any and all liabilities or expenses
to which they may be subjected by reason of any act or failure to act with respect to their duties on behalf of the Plan, except in circumstances
involving such person’s bad faith or willful misconduct.
Section
4. Awards.
(a)
General. Awards under the Plan may consist of Options as described in Section 7, Stock Awards as described in Section 8, Stock
Units as described in Section 9, SARs as described in Section 10, and Other Stock-Based Awards as described in Section 11. All Awards
shall be subject to the terms and conditions set forth herein and to such other terms and conditions consistent with this Plan as the
Committee deems appropriate and as are specified in writing by the Committee to the individual in the Award Agreement. All Awards shall
be made conditional upon the Participant’s acknowledgement, in writing or by acceptance of the Award, that all decisions and determinations
of the Committee shall be final and binding on the Participant, the Participant’s beneficiaries and any other person having or
claiming an interest under such Award. Awards under a particular Section of the Plan need not be uniform as among the Participants.
(b)
Minimum Vesting. Awards granted under the Plan shall include regular vesting schedules that provide that no portion of an Award
shall vest earlier than one year from the date of grant. However, (i) for purposes of Awards granted to Non-Employee Directors, such
Awards shall be deemed to satisfy this minimum vesting requirement if such Awards are granted on the date of the Corporation’s
annual meeting of stockholders and vest on the date of the Corporation’s annual meeting of stockholders immediately following the
date of grant (but not less than 50 weeks following the date of grant), and (ii) subject to adjustments made in accordance with Section
5(e) below, up to 5% of the shares of Common Stock authorized under the Plan as set forth in Section 5(a) as of the Effective Date may
be granted without regard to this minimum vesting requirement.
(c)
Dividends and Dividend Equivalents. Notwithstanding anything to the contrary herein, any dividends or Dividend Equivalents granted
in connection with Awards under the Plan shall vest and be paid only if and to the extent the underlying Awards vest and are paid.
Section
5. Shares Subject to the Plan.
(a)
Shares Authorized. Subject to adjustment as described below in Sections 5(b) and 5(e) below, the aggregate number of shares of
Common Stock that may be issued or transferred under the Plan shall not exceed 8,400,000 shares of Common Stock. In addition,
subject to adjustment as described below in Sections 5(b) and 5(e) below, shares of Common Stock reserved for issuance under the Prior
Plan that remain available for grant under the Prior Plan as of the Effective Date and shares of the Common Stock underlying any outstanding
award granted under the Prior Plan that, following the Effective Date, expires, or is terminated, surrendered, cancelled, or forfeited
or exchanged for any reason without issuance of such shares shall be available for new Awards under this Plan. Subject to adjustment
as described below in Sections 5(b) and 5(e) below, the aggregate number of shares of Common Stock that may be issued or transferred
under the Plan pursuant to Incentive Stock Options shall not exceed 8,400,000 shares of Common Stock.
(b)
Source of Shares; Share Counting. Shares issued or transferred under the Plan may be authorized but unissued shares of Common
Stock or reacquired shares of Common Stock, including shares purchased by the Corporation on the open market for purposes of the Plan.
If and to the extent Awards granted under the Plan expire, terminate or are surrendered cancelled, forfeited, exchanged or without having
been exercised, vested or paid in shares, the shares subject to such Awards shall again be available for purposes of the Plan. Shares
of Common Stock surrendered in payment of the Exercise Price of an Option (or an option granted under the Prior Plan) shall not be available
for re-issuance under the Plan. Shares of Common Stock withheld or surrendered for payment of taxes with respect to Awards (or awards
granted under the Prior Plan) shall not be available for re-issuance under the Plan. If SARs are granted, the full number of shares subject
to the SARs shall be considered issued under the Plan, without regard to the number of shares issued upon exercise of the SARs. To the
extent any Awards are paid in cash, and not in shares of Common Stock, any shares previously subject to such Awards shall again be available
for issuance or transfer under the Plan. For the avoidance of doubt, if shares are repurchased by the Corporation on the open market
with the proceeds of the Exercise Price of Options (including options granted under the Prior Plan), such shares may not again be made
available for issuance under the Plan.
(c)
Substitute Awards. Shares issued or transferred under Awards made pursuant to an assumption, substitution or exchange for previously
granted awards of a company acquired by the Corporation in a transaction (“Substitute Awards”) shall not reduce the
number of shares of Common Stock available under the Plan and available shares under a stockholder approved plan of an acquired company
(as appropriately adjusted to reflect the transaction) may be used for Awards under the Plan and shall not reduce the Plan’s share
reserve (subject to applicable stock exchange listing and Code requirements).
(d)
Individual Limits for Non-Employee Directors. Subject to adjustment as described below in Section 5(e), the maximum aggregate
grant date value of shares of Common Stock subject to Awards granted to any Non-Employee Director during any calendar year, taken together
with any cash fees earned by such Non-Employee Director for services rendered as a Non-Employee Director during the calendar year, shall
not exceed $500,000 in total value. For purposes of this limit, the value of such Awards shall be calculated based on the grant date
fair value of such Awards for financial reporting purposes and excluding the value of any Dividend Equivalents paid pursuant to any Award
granted in a previous year.
(e)
Adjustments. If there is any change in the number or kind of shares of Common Stock outstanding by reason of (i) a stock dividend,
spinoff, recapitalization, stock split, reverse stock split or combination or exchange of shares, (ii) a merger, reorganization or consolidation,
(iii) a reclassification or change in par value, or (iv) any other extraordinary or unusual event affecting the outstanding Common Stock
as a class without the Corporation’s receipt of consideration, or if the value of outstanding shares of Common Stock is substantially
reduced as a result of a spinoff or the Corporation’s payment of an extraordinary dividend or distribution, the maximum number
and kind of shares of Common Stock available for issuance under the Plan, the maximum amount of Awards which a Non-Employee Director
may receive in any year, the number and kind of shares covered by outstanding Awards, the number and kind of shares issued and to be
issued under the Plan, and the price per share or the applicable market value of such Awards shall be equitably adjusted by the Committee
to reflect any increase or decrease in the number of, or change in the kind or value of, the issued shares of Common Stock to preclude,
to the extent practicable, the enlargement or dilution of rights and benefits under the Plan and such outstanding Awards; provided,
however, that any fractional shares resulting from such adjustment shall be eliminated. In addition, the Committee is authorized
to make adjustments in the terms and conditions of, and the criteria included in, Awards in recognition of unusual or nonrecurring events
(including, without limitation, events described in the preceding sentence, and acquisitions and dispositions of businesses and assets)
affecting the Corporation, any Subsidiary or any business unit, or the financial statements of the Corporation or any Subsidiary, or
in response to changes in applicable laws, regulations, or accounting principles. In addition, in the event of a Change in Control, the
provisions of Section 13 of the Plan shall apply. Any adjustments to outstanding Awards shall be consistent with Section 409A or 424
of the Code, to the extent applicable. Subject to Section 18(b), the adjustments of Awards under this Section 5(e) shall include adjustment
of shares, Exercise Price of Options, base amount of SARs, Performance Goals or other terms and conditions, as the Committee deems appropriate.
The Committee shall have the sole discretion and authority to determine what appropriate adjustments shall be made and any adjustments
determined by the Committee shall be final, binding and conclusive.
Section 6. Eligibility for Participation.
(a)
Eligible Persons. All Employees and Non-Employee Directors shall be eligible to participate in the Plan. Key Advisors shall be
eligible to participate in the Plan if the Key Advisors render bona fide services to the Employer, the services are not in connection
with the offer and sale of securities in a capital-raising transaction and the Key Advisors do not directly or indirectly promote or
maintain a market for the Corporation’s securities.
(b)
Selection of Participants. The Committee shall select the Employees, Non-Employee Directors and Key Advisors to receive Awards
and shall determine the number of shares of Common Stock subject to a particular Award in such manner as the Committee determines.
Section
7. Options.
The
Committee may grant Options to an Employee, Non-Employee Director or Key Advisor upon such terms as the Committee deems appropriate.
The following provisions are applicable to Options:
(a)
Number of Shares. The Committee shall determine the number of shares of Common Stock that will be subject to each Award of Options
to Employees, Non-Employee Directors and Key Advisors.
(b)
Type of Option and Exercise Price.
(i)
The Committee may grant Incentive Stock Options or Nonqualified Stock Options or any combination of the two, all in accordance with the
terms and conditions set forth herein. Incentive Stock Options may be granted only to employees of the Corporation or any of its parent
or subsidiary corporations, as defined in Section 424 of the Code. Nonqualified Stock Options may be granted to Employees, Non-Employee
Directors and Key Advisors.
(ii)
The Exercise Price of Common Stock subject to an Option shall be determined by the Committee and shall be equal to or greater than the
Fair Market Value of a share of Common Stock on the date the Option is granted. However, an Incentive Stock Option may not be granted
to an Employee who, at the time of grant, owns stock possessing more than 10% of the total combined voting power of all classes of stock
of the Corporation, or any parent or subsidiary corporation of the Corporation, as defined in Section 424 of the Code, unless the Exercise
Price per share is not less than 110% of the Fair Market Value of a share of Common Stock on the date of grant.
(c)
Option Term. The Committee shall determine the term of each Option. The term of any Option shall not exceed ten years from the
date of grant. However, an Incentive Stock Option that is granted to an Employee who, at the time of grant, owns stock possessing more
than 10% of the total combined voting power of all classes of stock of the Corporation, or any parent or subsidiary corporation of the
Corporation, as defined in Section 424 of the Code, may not have a term that exceeds five years from the date of grant. Notwithstanding
the foregoing, in the event that on the last business day of the term of an Option (other than an Incentive Stock Option), the exercise
of the Option is prohibited by applicable law, including a prohibition on purchases or sales of Common Stock under the Corporation’s
insider trading policy, the term of the Option shall be extended for a period of 30 days following the end of the legal prohibition,
unless the Committee determines otherwise.
(d)
Exercisability of Options. Subject to Section 4(b), Options shall become exercisable in accordance with such terms and conditions,
consistent with the Plan, as may be determined by the Committee and specified in the Award Agreement, including upon the attainment of
specified Performance Goals. The Committee may accelerate the exercisability of any or all outstanding Options at any time for any reason.
(e)
Awards to Non-Exempt Employees. Notwithstanding the foregoing, Options granted to persons who are non-exempt employees under the
Fair Labor Standards Act of 1938, as amended, may not be exercisable for at least six months after the date of grant (except that such
Options may become exercisable, as determined by the Committee, upon the Participant’s death, Disability or retirement, or upon
a Change in Control or other circumstances permitted by applicable regulations).
(f)
Termination of Employment or Service. Except as provided in the Award Agreement, an Option may only be exercised while the Participant
is employed by, or providing services to, the Employer. The Committee shall determine in the Award Agreement under what circumstances
and during what time periods a Participant may exercise an Option after termination of employment or service.
(g)
Exercise of Options. A Participant may exercise an Option that has become exercisable, in whole or in part, by delivering a notice
of exercise to the Corporation. The Participant shall pay the Exercise Price for an Option as specified by the Committee (i) in cash
or by check, (ii) unless the Committee determines otherwise, by delivering shares of Common Stock owned by the Participant and having
a Fair Market Value on the date of exercise at least equal to the Exercise Price or by attestation (on a form prescribed by the Committee)
to ownership of shares of Common Stock having a Fair Market Value on the date of exercise at least equal to the Exercise Price, (iii)
by payment through a broker in accordance with procedures permitted by Regulation T of the Federal Reserve Board, (iv) if permitted by
the Committee, by withholding shares of Common Stock subject to the exercisable Option, which have a Fair Market Value on the date of
exercise equal to the Exercise Price, or (v) by such other method as the Committee may approve. Shares of Common Stock used to exercise
an Option shall have been held by the Participant for the requisite period of time necessary to avoid adverse accounting consequences
to the Corporation with respect to the Option. Payment for the shares to be issued or transferred pursuant to the Option, and any required
withholding taxes, must be received by the Corporation by the time specified by the Committee depending on the type of payment being
made, but in all cases prior to the issuance or transfer of such shares.
(h)
Limits on Incentive Stock Options. Each Incentive Stock Option shall provide that, if the aggregate Fair Market Value of the Common
Stock on the date of the grant with respect to which Incentive Stock Options are exercisable for the first time by a Participant during
any calendar year, under the Plan or any other stock option plan of the Corporation or a parent or subsidiary, exceeds $100,000, then
the Option, as to the excess, shall be treated as a Nonqualified Stock Option.
Section
8. Stock Awards.
The
Committee may issue or transfer shares of Common Stock to an Employee, Non-Employee Director or Key Advisor under a Stock Award, upon
such terms as the Committee deems appropriate. The following provisions are applicable to Stock Awards:
(a)
General Requirements. Shares of Common Stock issued or transferred pursuant to Stock Awards may be issued or transferred for consideration
or for no consideration, and subject to restrictions or no restrictions, as determined by the Committee. Subject to Section 4(b), the
Committee may, but shall not be required to, establish conditions under which restrictions on Stock Awards shall lapse over a period
of time or according to such other criteria as the Committee deems appropriate, including, without limitation, restrictions based on
the achievement of specific Performance Goals. The period of time during which the Stock Awards will remain subject to restrictions will
be designated in the Award Agreement as the “Restriction Period.”
(b)
Number of Shares. The Committee shall determine the number of shares of Common Stock to be issued or transferred pursuant to a
Stock Award and the restrictions applicable to such shares.
(c)
Requirement of Employment or Service. If the Participant ceases to be employed by, or provide service to, the Employer during
a period designated in the Award Agreement as the Restriction Period, or if other specified conditions are not met, the Stock Award shall
terminate as to all shares covered by the Award as to which the restrictions have not lapsed, and those shares of Common Stock must be
immediately returned to the Corporation. The Committee may, however, provide for complete or partial exceptions to this requirement as
it deems appropriate.
(d)
Restrictions on Transfer and Legend on Stock Certificate. During the Restriction Period, a Participant may not sell, assign, transfer,
pledge or otherwise dispose of the shares of a Stock Award except under Section 16 below. Unless otherwise determined by the Committee,
the Corporation will retain possession of certificates for shares of Stock Awards until all restrictions on such shares have lapsed.
Each certificate for a Stock Award, unless held by the Corporation, shall contain a legend giving appropriate notice of the restrictions
in the Award. The Participant shall be entitled to have the legend removed from the stock certificate covering the shares subject to
restrictions when all restrictions on such shares have lapsed. The Committee may determine that the Corporation will not issue certificates
for Stock Awards until all restrictions on such shares have lapsed.
(e)
Right to Vote and to Receive Dividends. Unless the Committee determines otherwise, during the Restriction Period, the Participant
shall have the right: (i) to vote shares of Stock Awards and (ii) subject to Section 4(b), to receive any dividends or other distributions
paid on such shares, subject to any restrictions deemed appropriate by the Committee, including, without limitation, the achievement
of specific Performance Goals.
(f)
Lapse of Restrictions. All restrictions imposed on Stock Awards shall lapse upon the expiration of the applicable Restriction
Period and the satisfaction of all conditions, if any, imposed by the Committee. The Committee may determine, as to any or all Stock
Awards, that the restrictions shall lapse without regard to any Restriction Period.
Section
9. Stock Units.
The
Committee may grant Stock Units, each of which shall represent one hypothetical share of Common Stock, to an Employee, Non-Employee Director
or Key Advisor upon such terms and conditions as the Committee deems appropriate. The following provisions are applicable to Stock Units:
(a)
Crediting of Units. Each Stock Unit shall represent the right of the Participant to receive a share of Common Stock or an amount
of cash based on the value of a share of Common Stock, if and when specified conditions are met. All Stock Units shall be credited to
bookkeeping accounts established on the Corporation’s records for purposes of the Plan.
(b)
Terms of Stock Units. Subject to Section 4(b), the Committee may grant Stock Units that vest and are payable if specified Performance
Goals or other conditions are met, or under other circumstances. Stock Units may be paid at the end of a specified performance period
or other period, or payment may be deferred to a date authorized by the Committee. The Committee may accelerate vesting or payment, as
to any or all Stock Units at any time for any reason, provided such acceleration complies with Section 409A of the Code. The Committee
shall determine the number of Stock Units to be granted and the requirements applicable to such Stock Units.
(c)
Requirement of Employment or Service. If the Participant ceases to be employed by, or provide service to, the Employer prior to
the vesting of Stock Units, or if other conditions established by the Committee are not met, the Participant’s Stock Units shall
be forfeited. The Committee may, however, provide for complete or partial exceptions to this requirement as it deems appropriate.
(d)
Payment With Respect to Stock Units. Payments with respect to Stock Units shall be made in cash, Common Stock or any combination
of the foregoing, as the Committee shall determine.
Section
10. Stock Appreciation Rights.
The
Committee may grant SARs to an Employee, Non-Employee Director or Key Advisor separately or in tandem with any Option. The following
provisions are applicable to SARs:
(a)
General Requirements. The Committee may grant SARs to an Employee, Non-Employee Director or Key Advisor separately or in tandem
with any Option (for all or a portion of the applicable Option). Tandem SARs may be granted either at the time the Option is granted
or at any time thereafter while the Option remains outstanding; provided, however, that, in the case of an Incentive Stock Option,
SARs may be granted only at the time of the grant of the Incentive Stock Option. The Committee shall establish the base amount of the
SAR at the time the SAR is granted. The base amount of each SAR shall be equal to or greater than the Fair Market Value of a share of
Common Stock as of the date of grant of the SAR. The term of any SAR shall not exceed ten years from the date of grant. Notwithstanding
the foregoing, in the event that on the last business day of the term of a SAR, the exercise of the SAR is prohibited by applicable law,
including a prohibition on purchases or sales of Common Stock under the Corporation’s insider trading policy, the term shall be
extended for a period of 30 days following the end of the legal prohibition, unless the Committee determines otherwise.
(b)
Tandem SARs. In the case of tandem SARs, the number of SARs granted to a Participant that shall be exercisable during a specified
period shall not exceed the number of shares of Common Stock that the Participant may purchase upon the exercise of the related Option
during such period. Upon the exercise of an Option, the SARs relating to the Common Stock covered by such Option shall terminate. Upon
the exercise of SARs, the related Option shall terminate to the extent of an equal number of shares of Common Stock.
(c)
Exercisability. Subject to Section 4(b), a SAR shall be exercisable during the period specified by the Committee in the Award
Agreement and shall be subject to such vesting and other restrictions as may be specified in the Award Agreement, including the attainment
of specified Performance Goals. The Committee may accelerate the exercisability of any or all outstanding SARs at any time for any reason.
SARs may only be exercised while the Participant is employed by, or providing service to, the Employer or during the applicable period
after termination of employment or service as specified by the Committee. A tandem SAR shall be exercisable only during the period when
the Option to which it is related is also exercisable.
(d)
Awards to Non-Exempt Employees. Notwithstanding the foregoing, SARs granted to persons who are non-exempt employees under the
Fair Labor Standards Act of 1938, as amended, may not be exercisable for at least six months after the date of grant (except that such
SARs may become exercisable, as determined by the Committee, upon the Participant’s death, Disability or retirement, or upon a
Change in Control or other circumstances permitted by applicable regulations).
(e)
Value of SARs. When a Participant exercises SARs, the Participant shall receive in settlement of such SARs an amount equal to
the value of the stock appreciation for the number of SARs exercised. The stock appreciation for a SAR is the amount by which the Fair
Market Value of the underlying Common Stock on the date of exercise of the SAR exceeds the base amount of the SAR as described in Section
10(a).
(f)
Form of Payment. The appreciation in a SAR shall be paid in shares of Common Stock, cash or any combination of the foregoing,
as the Committee shall determine. For purposes of calculating the number of shares of Common Stock to be received, shares of Common Stock
shall be valued at their Fair Market Value on the date of exercise of the SAR.
Section
11. Other Stock-Based Awards.
The
Committee may grant Other Stock-Based Awards, which are awards (other than those described in Sections 7, 8, 9 and 10 of the Plan) that
are based on or measured by Common Stock, to any Employee, Non-Employee Director or Key Advisor, on such terms and conditions as the
Committee shall determine. Subject to Section 4(b), Other Stock-Based Awards may be awarded subject to the achievement of Performance
Goals or other criteria or other conditions and may be payable in cash, Common Stock or any combination of the foregoing, as the Committee
shall determine.
Section
12. Dividend Equivalents.
The
Committee may grant Dividend Equivalents in connection with Stock Units or Other Stock-Based Awards in an applicable Award Agreement
or at any point following the grant of such Award. Subject to Section 4(c), Dividend Equivalents may be accrued as contingent cash obligations
and may be payable in cash or shares of Common Stock, and upon such terms and conditions as the Committee shall determine. For the avoidance
of doubt, dividends or Dividend Equivalents shall not be granted in connection with Options or SARs.
Section
13. Consequences of a Change in Control.
(a)
Assumption of Outstanding Awards. Upon a Change in Control where the Corporation is not the surviving corporation (or survives
only as a subsidiary of another corporation), unless the Committee determines otherwise, all outstanding Awards that are not exercised
or paid at the time of the Change in Control shall be assumed by, or replaced with grants (which may be in respect to cash, securities,
or a combination thereof) that have comparable terms by, the surviving corporation (or a parent or subsidiary of the surviving corporation).
After a Change in Control, references to the “Corporation” as they relate to employment matters shall include the successor
employer in the transaction, subject to applicable law. For purposes of the foregoing, an Award under the Plan shall not be treated as
continued, assumed, or replaced on comparable terms unless it is continued, assumed, or replaced with substantially equivalent terms,
including, without limitation, the same vesting terms.
(b)
Vesting Upon Certain Terminations of Employment. Unless the Committee determines otherwise or the applicable Award Agreement provides
otherwise, if a Participant’s employment or services terminate by reason of an Involuntary Termination upon or within 12 months
following a Change in Control, the Participant’s outstanding Awards shall become fully vested as of the date of such termination;
provided that if the vesting of any such Awards is based, in whole or in part, on performance, the applicable Award Agreement
shall specify how the portion of the Award that becomes vested pursuant to this Section 13(b) shall be calculated.
(c)
Other Alternatives. In the event of a Change in Control, if any outstanding Awards are not assumed by, or replaced with grants
that have comparable terms by, the surviving corporation (or a parent or subsidiary of the surviving corporation), the Committee may
(but is not obligated to) make adjustments to the terms and conditions of outstanding Awards, including, without limitation, taking any
of the following actions (or combination thereof) with respect to any or all outstanding Awards, without the consent of any Participant:
(i) the Committee may determine that outstanding Options and SARs shall automatically accelerate and become fully exercisable and the
restrictions and conditions on outstanding Stock Awards, Stock Units, Other Stock-Based Awards and Dividend Equivalents shall immediately
lapse; (ii) the Committee may determine that Participants shall receive a payment in settlement of outstanding Stock Units, Other Stock-Based
Awards or Dividend Equivalents, in such amount and form as may be determined by the Committee; (iii) the Committee may require that Participants
surrender their outstanding Options and SARs in exchange for a payment by the Corporation, in cash or Common Stock as determined by the
Committee, in an amount equal to the amount, if any, by which the then Fair Market Value of the shares of Common Stock subject to the
Participant’s unexercised Options and SARs exceeds the Option Exercise Price or SAR base amount, and (iv) after giving Participants
an opportunity to exercise all of their outstanding Options and SARs, the Committee may terminate any or all unexercised Options and
SARs at such time as the Committee deems appropriate. Such surrender, termination or payment shall take place as of the date of the Change
in Control or such other date as the Committee may specify. Without limiting the foregoing, if the per share Fair Market Value of the
Common Stock does not exceed the per share Option Exercise Price or SAR base amount, as applicable, the Corporation shall not be required
to make any payment to the Participant upon surrender of the Option or SAR.
Section
14. Deferrals.
The
Committee may permit or require a Participant to defer receipt of the payment of cash or the delivery of shares that would otherwise
be due to such Participant in connection with any Award. If any such deferral election is permitted or required, the Committee shall
establish rules and procedures for such deferrals and may provide for interest or other earnings to be paid on such deferrals. The rules
and procedures for any such deferrals shall be consistent with applicable requirements of Section 409A of the Code.
Section
15. Withholding of Taxes.
(a)
Required Withholding. All Awards under the Plan shall be subject to applicable United States federal (including FICA), state and
local, foreign country or other tax withholding requirements. The Employer may require that the Participant or other person receiving
Awards or exercising Awards pay to the Employer an amount sufficient to satisfy such tax withholding requirements with respect to such
Awards, or the Employer may deduct from other wages and compensation paid by the Employer the amount of any withholding taxes due with
respect to such Awards, or the Employer may take such other action as the Committee may deem advisable to enable the Employer to satisfy
obligations for the payment of withholding taxes and other tax obligations relating to any Award.
(b)
Share Withholding. The Committee may permit or require the Employer’s tax withholding obligation with respect to Awards
paid in Common Stock to be satisfied by having shares withheld up to an amount that does not exceed the Participant’s applicable
withholding tax rate for United States federal (including FICA), state and local, foreign country or other tax liabilities. The Committee
may, in its discretion, and subject to such rules as the Committee may adopt, allow Participants to elect to have such share withholding
applied to all or a portion of the tax withholding obligation arising in connection with any particular Award. Unless the Committee determines
otherwise, share withholding for taxes shall not exceed the Participant’s minimum applicable tax withholding amount.
Section
16. Transferability of Awards.
(a)
Nontransferability of Awards. Except as described in subsection (b) below, only the Participant may exercise rights under an Award
during the Participant’s lifetime. A Participant may not transfer those rights except (i) by will or by the laws of descent and
distribution or (ii) with respect to Awards other than Incentive Stock Options, pursuant to a domestic relations order. When a Participant
dies, the personal representative or other person entitled to succeed to the rights of the Participant may exercise such rights. Any
such successor must furnish proof satisfactory to the Corporation of the successor’s right to receive the Award under the Participant’s
will or under the applicable laws of descent and distribution.
(b)
Transfer of Nonqualified Stock Options and Stock Awards. Notwithstanding the foregoing, the Committee may provide, in an Award
Agreement or at such other time after the grant of an award, that a Participant may transfer Nonqualified Stock Options or Stock Awards
to family members, or one or more trusts or other entities for the benefit of or owned by family members, consistent with the applicable
securities laws, according to such terms as the Committee may determine; provided that the Participant receives no consideration
for the transfer of an Option or Stock Award and the transferred Option or Stock Award shall continue to be subject to the same terms
and conditions as were applicable to the Option or Stock Award immediately before the transfer.
Section
17. Requirements for Issuance or Transfer of Shares
No
Common Stock shall be issued or transferred in connection with any Award hereunder unless and until all legal requirements applicable
to the issuance or transfer of such Common Stock have been complied with to the satisfaction of the Committee. The Committee shall have
the right to condition any Award on the Participant’s undertaking in writing to comply with such restrictions on the Participant’s
subsequent disposition of the shares of Common Stock as the Committee shall deem necessary or advisable, and certificates representing
such shares may be legended to reflect any such restrictions. Certificates representing shares of Common Stock issued or transferred
under the Plan may be subject to such stop-transfer orders and other restrictions as the Committee deems appropriate to comply with applicable
laws, regulations and interpretations, including any requirement that a legend be placed thereon.
Section
18. Amendment and Termination of the Plan.
(a)
Amendment. The Board may amend or terminate the Plan at any time; provided, however, that the Board shall not amend the
Plan without stockholder approval if such approval is required in order to comply with the Code or other applicable law, or to comply
with applicable stock exchange requirements.
(b)
No Repricing of Options or SARs. Except in connection with a corporate transaction involving the Corporation (including, without
limitation, any stock dividend, distribution (whether in the form of cash, Common Stock, other securities or property), stock split,
extraordinary cash dividend, recapitalization, change in control, reorganization, merger, consolidation, split-up, spin-off, combination,
repurchase or exchange of shares of Common Stock or other securities, or similar transactions), the Corporation may not, without obtaining
stockholder approval, (i) amend the terms of outstanding Options or SARs to reduce the Exercise Price of such outstanding Options or
base price of such SARs, (ii) cancel outstanding Options or SARs in exchange for Options or SARs with an Exercise Price or base price,
as applicable, that is less than the Exercise Price or base price of the original Options or SARs or (iii) cancel outstanding Options
or SARs with an Exercise Price or base price, as applicable, above the current stock price in exchange for cash or other securities.
(c)
Termination of Plan. The Plan shall terminate on the day immediately preceding the tenth anniversary of its Effective Date, unless
the Plan is terminated earlier by the Board or is extended by the Board with the approval of the stockholders.
(d)
Termination and Amendment of Outstanding Awards. A termination or amendment of the Plan that occurs after an Award is made shall
not materially impair the rights of a Participant with respect to such Award unless the Participant consents or unless the Committee
acts under Section 19(f) below. The termination of the Plan shall not impair the power and authority of the Committee with respect to
an outstanding Award. Whether or not the Plan has terminated, an outstanding Award may be terminated or amended under Section 19(f) below
or may be amended by agreement of the Corporation and the Participant consistent with the Plan.
Section
19. Miscellaneous.
(a)
Awards in Connection with Corporate Transactions and Otherwise. Nothing contained in the Plan shall be construed to (i) limit
the right of the Committee to make Awards under the Plan in connection with the acquisition, by purchase, lease, merger, consolidation
or otherwise, of the business or assets of any corporation, firm or association, including Awards to employees thereof who become Employees,
or (ii) limit the right of the Corporation to grant stock options or make other awards outside of the Plan. The Committee may make an
Award to an employee of another corporation who becomes an Employee by reason of a corporate merger, consolidation, acquisition of stock
or property, reorganization or liquidation involving the Corporation, in substitution for a stock option or stock awards grant made by
such corporation. Notwithstanding anything in the Plan to the contrary, the Committee may establish such terms and conditions of the
new Awards as it deems appropriate, including setting the Exercise Price of Options or the base price of SARs at a price necessary to
retain for the Participant the same economic value as the prior options or rights.
(b)
Governing Document. The Plan shall be the controlling document. No other statements, representations, explanatory materials or
examples, oral or written, may amend the Plan in any manner. The Plan shall be binding upon and enforceable against the Corporation and
its successors and assigns.
(c)
Funding of the Plan. The Plan shall be unfunded. The Corporation shall not be required to establish any special or separate fund
or to make any other segregation of assets to assure the payment of any Awards under the Plan.
(d)
Rights of Participants. Nothing in the Plan shall entitle any Employee, Non-Employee Director, Key Advisor or other person to
any claim or right to receive an Award under the Plan. Neither the Plan nor any action taken hereunder shall be construed as giving any
individual any rights to be retained by or in the employ of the Employer or any other employment rights.
(e)
No Fractional Shares. No fractional shares of Common Stock shall be issued or delivered pursuant to the Plan or any Award. Except
as otherwise provided under the Plan, the Committee shall determine whether cash, other awards or other property shall be issued or paid
in lieu of such fractional shares or whether such fractional shares or any rights thereto shall be forfeited or otherwise eliminated.
(f)
Compliance with Law.
(i)
The Plan, the exercise of Options and SARs and the obligations of the Corporation to issue or transfer shares of Common Stock under Awards
shall be subject to all applicable laws and regulations, and to approvals by any governmental or regulatory agency as may be required.
With respect to persons subject to Section 16 of the Exchange Act, it is the intent of the Corporation that the Plan and all transactions
under the Plan comply with all applicable provisions of Rule 16b-3 or its successors under the Exchange Act. In addition, it is the intent
of the Corporation that Incentive Stock Options comply with the applicable provisions of Section 422 of the Code, and that, to the extent
applicable, Awards comply with the requirements of Section 409A of the Code. To the extent that any legal requirement of Section 16 of
the Exchange Act or Section 422 or 409A of the Code as set forth in the Plan ceases to be required under Section 16 of the Exchange Act
or Section 422 or 409A of the Code, that Plan provision shall cease to apply. The Committee may revoke any Award if it is contrary to
law or modify an Award to bring it into compliance with any valid and mandatory government regulation. The Committee may also adopt rules
regarding the withholding of taxes on payments to Participants. The Committee may, in its sole discretion, agree to limit its authority
under this Section.
(ii)
The Plan is intended to comply with the requirements of Section 409A of the Code, to the extent applicable. Each Award shall be construed
and administered such that the Award either (A) qualifies for an exemption from the requirements of Section 409A of the Code or (B) satisfies
the requirements of Section 409A of the Code. If an Award is subject to Section 409A of the Code, (I) distributions shall only be made
in a manner and upon an event permitted under Section 409A of the Code, (II) payments to be made upon a termination of employment or
service shall only be made upon a “separation from service” under Section 409A of the Code, (III) unless the Award specifies
otherwise, each installment payment shall be treated as a separate payment for purposes of Section 409A of the Code, and (IV) in no event
shall a Participant, directly or indirectly, designate the calendar year in which a distribution is made except in accordance with Section
409A of the Code.
(iii)
Any Award that is subject to Section 409A of the Code and that is to be distributed to a Key Employee (as defined below) upon separation
from service shall be administered so that any distribution with respect to such Award shall be postponed for six months following the
date of the Participant’s separation from service, if required by Section 409A of the Code. If a distribution is delayed pursuant
to Section 409A of the Code, the distribution shall be paid within 15 days after the end of the six-month period. If the Participant
dies during such six-month period, any postponed amounts shall be paid within 90 days of the Participant’s death. The determination
and identification of “Key Employees”, including the number and identity of persons considered Key Employees
and the identification date, shall be made by the Committee or its delegate each year in accordance with Section 416(i) of the Code and
the “specified employee” requirements of Section 409A of the Code.
(iv)
Notwithstanding anything in the Plan or any Award agreement to the contrary, each Participant shall be solely responsible for the tax
consequences of Awards under the Plan, and in no event shall the Corporation or any Subsidiary or Affiliate of the Corporation have any
responsibility or liability if an Award does not meet any applicable requirements of Section 409A of the Code. Although the Corporation
intends to administer the Plan to prevent taxation under Section 409A of the Code, the Corporation does not represent or warrant that
the Plan or any Award complies with any provision of federal, state, local or other tax law.
(g)
Awards in Foreign Countries; Establishment of Subplans. The Committee has the authority to award Awards to Participants who are
foreign nationals or employed outside the United States on any different terms and conditions than those specified in the Plan that the
Committee, in its discretion, believes to be necessary or desirable to accommodate differences in applicable law, tax policy, or custom,
while furthering the purposes of the Plan. The Board may from time to time establish one or more sub-plans under the Plan for purposes
of satisfying applicable blue sky, securities or tax laws of various jurisdictions. The Board shall establish such sub-plans by adopting
supplements to the Plan setting forth (i) such limitations on the Committee’s discretion under the Plan as the Board deems necessary
or desirable and (ii) such additional terms and conditions not otherwise inconsistent with the Plan as the Board shall deem necessary
or desirable. All supplements adopted by the Board shall be deemed to be part of the Plan, but each supplement shall apply only to Participants
within the affected jurisdiction and the Employer shall not be required to provide copies of any supplement to Participants in any jurisdiction
that is not affected. Notwithstanding the foregoing, the Committee may not approve any sub-plan inconsistent with the terms or share
limits in the Plan or which would otherwise cause the Plan to cease to satisfy any conditions under Rule 16b-3 under the Exchange Act.
(h)
Company Policies and Clawback Rights.
(i)
All Awards under the Plan shall be subject to any applicable clawback or recoupment policies, share trading policies and other policies
that may be approved or implemented by the Board or the Committee from time to time, whether or not approved before or after the Effective
Date. The Corporation may offset any payments due under this Plan or in connection with an Award to a Participant by any required repayments
that such Participant under any applicable clawback or recoupment policy; provided than any application of a clawback policy or
offset in respect thereof will be applied consistent with Section 409A (as defined below).
(ii)
Subject to the requirements of applicable law, the Committee may provide in any Award Agreement that, if a Participant breaches any restrictive
covenant obligation or agreement between the Participant and the Employer (which may be set forth in any Award Agreement) or otherwise
engages in activities that constitute Misconduct either while employed by, or providing service to, the Employer or within a specified
period of time thereafter, all Awards held by the Participant shall terminate, and the Corporation may rescind any exercise of an Option
or SAR and the vesting of any other Award and delivery of shares upon such exercise or vesting (including pursuant to dividends and Dividend
Equivalents), as applicable on such terms as the Committee shall determine, including the right to require that in the event of any such
rescission, (A) the Participant shall return to the Corporation the shares received upon the exercise of any Option or SAR and/or the
vesting and payment of any other Award (including pursuant to dividends and Dividend Equivalents) or, (B) if the Participant no longer
owns the shares, the Participant shall pay to the Corporation the amount of any gain realized or payment received as a result of any
sale or other disposition of the shares (or, in the event the Participant transfers the shares by gift or otherwise without consideration,
the Fair Market Value of the shares on the date of the breach of the restrictive covenant agreement (including a Participant’s
Award Agreement containing restrictive covenants) or activity constituting Misconduct), net of the price originally paid by the Participant
for the shares. Payment by the Participant shall be made in such manner and on such terms and conditions as may be required by the Committee.
The Employer shall be entitled to set off against the amount of any such payment any amounts otherwise owed to the Participant by the
Employer.
(i)
Governing Law; Jurisdiction. The validity, construction, interpretation and effect of the Plan and Award Agreements issued under
the Plan shall be governed and construed by and determined in accordance with the laws of the State of Delaware, without giving effect
to the conflict of laws provisions thereof. Any action arising out of, or relating to, any of the provisions of the Plan and Awards made
hereunder shall be brought only in the United States District Court for the District of Delaware, or if such court does not have jurisdiction
or will not accept jurisdiction, in any court of general jurisdiction in the State of Delaware, and the jurisdiction of such court in
any such proceeding shall be exclusive.
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Oct 2024 to Nov 2024
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Nov 2023 to Nov 2024
